Methods for detecting and treating cavernous angioma

WO2024168236A3PCT designated stage expired Publication Date: 2024-11-07UNIVERSITY OF CHICAGO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/015143
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-09
Filing Date
2024-02-09
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current methods for diagnosing and treating cerebral cavernous malformations (CCMs) lack effective biomarkers for accurately assessing disease status and progression, leading to challenges in selecting aggressive cases for clinical trials and monitoring therapy efficacy.

Method used

The development of methods involving the evaluation of specific metabolites and biomarkers in biological samples, such as sCD14, CRP, VEGF, Linoleic Acid, miR-20a-5p, and miR-486-5p, to diagnose and prognose CCMs, using canonical values calculated from these markers to determine disease presence and aggressiveness.

Benefits of technology

These methods enable accurate diagnosis and prognosis of CCMs, allowing for targeted therapeutic interventions and monitoring of treatment efficacy, improving clinical management of the disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024015143_07112024_PF_FP_ABST
    Figure US2024015143_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The disclosure provides methods for diagnosing, prognosing, and treating cavernous angioma (CA). Also provided are methods for determining the efficacy of therapeutic treatments for CA, such as those that may be in a clinical trial setting or administered by a health care professional. Aspects of the disclosure relate to a method for treating cavernous angioma (CA) in a subject, the method comprising administering a therapy to a subject that has been evaluated for one or more metabolites and / or one or more biomarkers in a biological sample from the subject. Aspects relate to a method for prognosing or diagnosing CA in a subject, the method comprising evaluating one or more metabolites and / or one or more biomarkers in a biological sample from the subject. Aspects relate to a method for evaluating a subject comprising evaluating one or more metabolites and / or one or more biomarkers in a biological sample from the subject.
Need to check novelty before this filing date? Find Prior Art

Description

METHODS FOR DETECTING AND TREATING CAVERNOUS ANGIOMA CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority of U.S. Provisional Application No. 63 / 444,508 filed February 9, 2023, which is hereby incorporated by reference in its entirety. DESCRIPTION

[0002] This invention was made with government support under grant number NS114552 awarded by the National Institutes of Health. The government has certain rights in this invention. I. Field of the Invention

[0003] The present invention relates generally to the fields of molecular biology and therapeutic diagnosis. More particularly, it concerns methods and compositions involving prognosing, diagnosing, and treating cerebral cavernous malformations. II. Background

[0004] Cerebral cavernous malformations (CCMs), also known as cavernous angiomas, are enlarged blood-filled caverns prone to hemorrhage due to dysfunctional vessel wall angioarchitecture (J. Koskimaki, et al. JCI Insight 4, (2019)). A fraction of CCM patients manifest familial disease, with an autosomal dominant inheritance of a heterozygous germline loss of function mutation in one of three documented genes, CCM1 / KRIT1, CCM2 / Malcavernin, or CCM3 / PDCD10 (J. Koskimaki, et al. JCI Insight 4, (2019)). These familial cases develop new hemorrhagic brain lesions throughout their life, predisposing them to a risk of symptomatic hemorrhage, seizures, and / or focal neurological deficits (J. Koskimaki, et al. JCI Insight 4, (2019)). The natural clinical course of individual lesions is relatively benign (J. Koskimaki, et al., Acta Neuropathol Commun 7, 132 (2019)), but some cases acquire an aggressive course due to a number of mechanisms, including those related to the microbiome and gut-brain axis (M. A. Lopez-Ramirez, et al., J Exp Med 214, 3331-3346 (2017); R. Girard, et al., Transl Stroke Res 9, 34-43 (2018); Girard, H. A. et al., Growth. Circ Res 122, 1716-1721 (2018)), lesional anticoagulant domains (S. B. Lyne, et al., JCI Insight 4, (2019)), and additional somatic mutations involving the activation of oncogenes (A. Rueda, et al., Nucleic Acids Res 43, W467-473 (2015)). The CCM3 / PDCD10 disease also manifests exceptional aggressiveness with greater lesion burden and earlier disease manifestations than other genotypes (T. Iguchi, et al., Transcription Pcr. J Vis Exp, (2018)). The more common sporadic lesions manifest solitary lesions in the brain, harboring somatic mutations of the same CCM138923491.1 - 1 -genes (David A. McDonald, et al., Human Molecular Genetics, Volume 23, Issue 16, 15 August 2014, Pages 4357–4370). Hence, the pathobiology of sporadic and familial cases reflect common gene disturbances and signaling aberrations. Surgical excision of symptomatic CCM lesions is a current therapeutic option, but has serious morbidity and high costs, and obvious limitations with multiple lesions (J. Koskimaki, et al. JCI Insight 4, (2019)). Efforts are underway to develop therapeutic targets based on phenotypic rescue of pathogenetic signaling aberrations (Awad IA, et al., Invited review, 75thAnniversary issue. J Neurosurg 131 (1):1-13, 2019; Snellings DA, et al., Circ Res 129(1):195-215, 2021.). Gene restoration therapies are also being pursued with viral vectors for familial disease (H. S. McKay, et al., Cytokine 85, 71-79 (2016)).

[0005] There is an ongoing search for facile biomarkers that can accurately reflect disease status and lesional activity of CCMs, to guide the selection of aggressive cases for clinical trials and to monitor the impact of therapies (B. D. Fleming, et al., J Leukoc Biol 98, 395-407 (2015); D. C. Clarke, et al., Proteomics 12, 245-262 (2013); J. T. Leek, et al., Bioinformatics 28, 882- 883 (2012); W. J. Youden, Cancer 3, 32-35 (1950)). These include discrete contexts of use, including the diagnosis of disease or its permissive host, categorizing disease aggressiveness, and defining CCM cases that bled or would bleed, hence portending greater risk. Thus, there is a need in the art for biomarkers for CCM that are indicative of disease level and progression. SUMMARY OF THE INVENTION

[0006] The current disclosure provides for methods for diagnosing, prognosing, and treating cavernous angioma (CA). Also provided are methods for determining the efficacy of therapeutic treatments for CA, such as those that may be in a clinical trial setting or administered by a health care professional. Accordingly, aspects of the disclosure relate to a method for treating cavernous angioma (CA) in a subject, the method comprising administering a therapy to a subject that has been evaluated for one or more metabolites and / or one or more biomarkers in a biological sample from the subject. A further aspect relates to a method for prognosing or diagnosing CA in a subject, the method comprising evaluating one or more metabolites and / or one or more biomarkers in a biological sample from the subject. A further aspect relates to a method for evaluating a subject comprising evaluating one or more metabolites and / or one or more biomarkers in a biological sample from the subject. Also described are kits comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 detection agents for determining levels of one or more biomarkers or metabolites for CA.138923491.1 - 2 -

[0007] In aspects of the disclosure, the metabolite may comprise or consist of one or more of one or more of: 1-(9Z-Octadecenoyl)-sn-glycero-3-phosphocholine, Linoleic Acid, 1- Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, Cholic acid, cis-9-Hexadecenoic acid, Etiocholanedione, Glycocholic acid, Glycodeoxycholic acid, Deoxycholic acid, Hydroxypalmitic acid, Hypoxanthine, LysoPE 18:2, Phenylalanylphenylalanine, Tauroursodeoxycholic acid, Urobilin, 1-Oleoyl-sn-glycero-3-phosphoethanolamine, Arachidonic acid (cis-5,8,11,14-Eicosatetraenoic acid), 1-Palmitoyl-sn-glycero-3- phosphocholine, 1-Stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, 7a-Hydroxy-3- oxo-4-cholestenoic acid (7alpha-Hydroxy-3-oxo-4-cholestenoic acid), Bilirubin, cis-9- Hexadecenoic acid, Decanoyl-L-carnitine, palmitoleic acid, LysoPC 18:1, LysoPE 16:0, DL- beta-Hydroxypalmitic acid, LysoPE 18:1, LysoPC 16:0, and LysoPE 18:0. It is specifically contemplated that, in some aspects, one of more of the preceding metabolites may be excluded. For example, in certain aspects, the method comprises not measuring one or more of 1-(9Z- Octadecenoyl)-sn-glycero-3-phosphocholine, Linoleic Acid, 1-Palmitoyl-2-hydroxy-sn- glycero-3-phosphoethanolamine, Cholic acid, cis-9-Hexadecenoic acid, Etiocholanedione, Glycocholic acid, Glycodeoxycholic acid, Deoxycholic acid, Hydroxypalmitic acid, Hypoxanthine, LysoPE 18:2, Phenylalanylphenylalanine, Tauroursodeoxycholic acid, Urobilin, 1-Oleoyl-sn-glycero-3-phosphoethanolamine, Arachidonic acid (cis-5,8,11,14- Eicosatetraenoic acid), 1-Palmitoyl-sn-glycero-3-phosphocholine, 1-Stearoyl-2-hydroxy-sn- glycero-3-phosphoethanolamine, 7a-Hydroxy-3-oxo-4-cholestenoic acid (7alpha-Hydroxy-3- oxo-4-cholestenoic acid), Bilirubin, cis-9-Hexadecenoic acid, Decanoyl-L-carnitine, palmitoleic acid, LysoPC 18:1, LysoPE 16:0, DL-beta-Hydroxypalmitic acid, LysoPE 18:1, LysoPC 16:0, and LysoPE 18:0.

[0008] In aspects of the disclosure, the biomarker may comprise or consist of one or more of C-reactive protein (CRP), Endoglin, Interferon gamma (IFNγ), IL-1β, IL-6, IL-7, IL-10, IL- 16, IL17, Soluble cluster of differentiation 14 (sCD14), Tumor necrosis factors (TNF), Vascular endothelial growth factor (VEGF), Soluble toll-like receptor4 (sTLR4), Lipopolysaccharide binding protein (LBP), Thrombomodulin, Thrombospondin-1 (TSP-1), Thrombospondin-2 (TSP-2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), miR-25-3p, miR-4732-3p, miR-486-3p, miR-486-5p, miR-7706, miR-144-5p, miR-92a-3p, miR-16-5p, miR-182-5p, miR-1180-3p, miR-629-5p, miR-151b, miR-183-5p, miR-20a-5p, miR-30d-5p, miR-451a, miR-660-5p, miR-501-3p, and miR-144-3p. It is specifically contemplated that, in some aspects, one of more of the preceding biomarkers may be excluded. For example, in138923491.1 - 3 -certain aspects, the method comprises not measuring one or more of C-reactive protein (CRP), Endoglin, Interferon gamma (IFNγ), IL-1β, IL-6, IL-7, IL-10, IL-16, IL17, Soluble cluster of differentiation 14 (sCD14), Tumor necrosis factors (TNF), Vascular endothelial growth factor (VEGF), Soluble toll-like receptor4 (sTLR4), Lipopolysaccharide binding protein (LBP), Thrombomodulin, Thrombospondin-1 (TSP-1), Thrombospondin-2 (TSP-2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), miR-25-3p, miR-4732-3p, miR-486-3p, miR-486-5p, miR- 7706, miR-144-5p, miR-92a-3p, miR-16-5p, miR-182-5p, miR-1180-3p, miR-629-5p, miR- 151b, miR-183-5p, miR-20a-5p, miR-30d-5p, miR-451a, miR-660-5p, miR-501-3p, and miR- 144-3p.

[0009] The subject may be one that has been evaluated for levels of or tthe evaluated level of biomarkers, which may or may not comprise or consist of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486-5p. The subject may be one that has been evaluated as having and / or diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486-5p relative to a control. The subject may be one that has been determined to have a canonical value, or the method may further comprise determining a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10]+316.54*[Linoleic Acid]r,- 6.06*[miR-20a-5p]r+5.41*[mir-25-3p]r+1.26*[miR-486-5p]r. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 (or any derivable range therein), wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10]+316.54*[Linoleic Acid]r,-6.06*[miR-20a-5p]r+5.41*[mir-25- 3p]r+1.26*[miR-486-5p]r.

[0010] The subject may be one that has been evaluated for levels of or the evaluated level of biomarkers, which may or may not comprise or consist of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, and miR-486- 5p. The subject may be one that has been evaluated as having and / or diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a- 3p, miR-25-3p, and miR-486-5p relative to a control. The subject may be one that has been determined to have a canonical value, or the method may further comprise determining a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-138923491.1 - 4 -0.36*[VEGF]-0.57*[IL-10]+336051.67*[Linoleic Acid]r,-19317.97*[glycodeoxycholic acid]r-6074*[miR-92a-3p]r+74219*[miR-25-3p]r+3248.33*[miR-486-5p]r. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -4, -3, -2, -1, 0, 1, 2, or 3 (or any derivable range therein), wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]- 0.57*[IL-10]+336051.67*[Linoleic Acid]r,-19317.97*[glycodeoxycholic acid]r-6074*[miR- 92a-3p]r+74219*[miR-25-3p]r+3248.33*[miR-486-5p]r.

[0011] The subject may be one that has been evaluated for levels of or the evaluated level of biomarkers, which may or may not comprise or consist of one or more of sCD14, CRP, VEGF, and IL-10. The subject may be one that has been evaluated as having and / or diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, and IL-10 relative to a control. The subject may be one that has been determined to have a canonical value, or the method may further comprise determining a canonical value, wherein the canonical value is equal to - 3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10]. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -8, -7, -6, -5, -4, -3, or -2 (or any derivable range therein), wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10].

[0012] The subject may be one that has been evaluated for levels of or the evaluated level of biomarkers, which may or may not comprise or consist of one or more of miR-16-5p, miR- 20a-5p, miR-25-3p, miR-92a-3p, and miR-486-5p. The subject may be one that has been evaluated as having and / or is diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of miR-16-5p, miR-20a- 5p, miR-25-3p, miR-92a-3p, and miR-486-5p relative to a control.

[0013] The subject may be one that has been determined to have a canonical value, or the method may further comprise determining a canonical value, wherein the canonical value is equal to 0.55*[ miR-16-5p]r-1.44*[miR-20a-5p]r+1.38*[miR-25-3p]r-1.04*[miR-92a- 3p]r+0.57*[miR-486-5p]r. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -2, -1, 0, 1, 2, or 3 (or any derivable range therein), wherein the canonical value is equal to 0.55*[ miR-16-5p]r-1.44*[miR-20a-5p]r+1.38*[miR-25-3p]r-1.04*[miR-92a-3p]r+0.57*[miR-486- 5p]r.138923491.1 - 5 -

[0014] The subject may be one that has been evaluated for levels of or tthe evaluated level of biomarkers, which may or may not comprise or consist of one or more of oleoyl-sn-glycero- 3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid. The subject may be one that has been evaluated as having and / or is diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of oleoyl-sn-glycero- 3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid relative to a control. The subject may be one that has been determined to have a canonical value, or the method may further comprise determining a canonical value, wherein the canonical value is equal to - 1248.41*[oleoyl-sn-glycero-3-phosphoethanolamine]r-17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -2, - 1.75, -1.5, -1.25, -1, -0.75, -0.5, -0.25, or 0 (or any derivable range therein), wherein the canonical value is equal to -1248.41*[oleoyl-sn-glycero-3-phosphoethanolamine]r- 17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r.

[0015] The subject may be one that has been evaluated for levels of or the evaluated level of biomarkers, which may or may not comprise or consist of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy-3-oxo-4-cholestenoic acid. The subject may be one that has been evaluated as having differential levels of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy-3-oxo-4- cholestenoic acid relative to a control. The subject may be one that has been determined to have a canonical value, or the method may further comprise determining a canonical value, wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4-cholestenoic acid] + 0.07. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy-3-oxo-4-cholestenoic acid relative to a control. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -20, -19, -18, - 17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any derivable range therein), wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4-138923491.1 - 6 -cholestenoic acid] + 0.07. The subject may be diagnosed as not having CA when a biological sample from the subject has been evaluated as not having differential levels of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy-3-oxo-4-cholestenoic acid relative to a control.

[0016] The subject may be one that has been evaluated for levels of or the evaluated level of biomarkers, which may or may not comprise or consist of one or more of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, and bilirubin. The subject may be one that has been evaluated as having differential levels of one or more of cis-9-hexadecenoic acid, 1- palmitoyl-sn-glycero-3-phosphocholine, and bilirubin relative to a control. The subject may be one that has been determined to have a canonical value, or the method may further comprise determining a canonical value, wherein the canonical value is equal to 3682.02 * [cis-9- hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn-glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.48. The subject may be diagnosed as having aggressive CA when a biological sample from the subject has been evaluated as having differential levels of one or more of cis- 9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, and bilirubin relative to a control. The subject may be diagnosed as having aggressive CA when a biological sample from the subject has been evaluated as having a canonical value of less than -5, -4.5, -4, -3.5, -3, - 2.5, -2, -1.5, -1, -0.5, 0, 0.5, 1, 1.5, 2, 2.5, or 3 (or any derivable range therein), wherein the canonical value is equal to 3682.02 * [cis-9-hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn- glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.48. The subject may be diagnosed as having non-aggressive CA when a biological sample from the subject has been evaluated as not having differential levels of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3- phosphocholine, and bilirubin relative to a control. The subject may be diagnosed as having non-aggressive CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -5, -4.5, -4, -3.5, -3, -2.5, -2, -1.5, -1, -0.5, 0, 0.5, 1, 1.5, 2, 2.5, or 3 (or any derivable range therein), wherein the canonical value is equal to 3682.02 * [cis-9- hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn-glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.48.

[0017] The subject may be one that has been evaluated for levels of or the evaluated level of biomarkers, which may or may not comprise decanoyl-L-carnitine. The subject may be one that has been evaluated as having differential levels of decanoyl-L-carnitine relative to a control. The subject may be one that has been determined to have a canonical value, or the method may further comprise determining a canonical value, wherein the canonical value is138923491.1 - 7 -equal to 1236.91 * [decanoyl-L-carnitine] – 0.37. The subject may be diagnosed as having familial CA when a biological sample from the subject has been evaluated as having differential levels of decanoyl-L-carnitine relative to a control. The subject may be diagnosed as having familial CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -2, -1.5, -1, -0.5, 0, 0.5, or 1 (or any derivable range therein), wherein the canonical value is equal to 1236.91 * [decanoyl-L-carnitine] – 0.37. The subject may be diagnosed as having sporadic CA when a biological sample from the subject has been evaluated as not having differential levels of decanoyl-L-carnitine relative to a control. The subject may be diagnosed as having sporadic CA when a biological sample from the subject has been evaluated as having a canonical value of less than -2, -1.5, -1, -0.5, 0, 0.5, or 1 (or any derivable range therein), wherein the canonical value is equal to 1236.91 * [decanoyl-L- carnitine] – 0.37.

[0018] One or more controls may be evaluated with the biomarkers or metabolites in the methods of the disclosure. CA may, in some aspects, be further defined as cavernous angioma with symptomatic hemorrhage (CASH). The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486-5p relative to a control. The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 (or any derivable range therein), wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL- 10]+316.54*[Linoleic Acid]r,-6.06*[miR-20a-5p]r+5.41*[mir-25-3p]r+1.26*[miR-486-5p]r. The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of sCD14, CRP, VEGF, IL- 10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, and miR-486-5p relative to a control. The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than 3, 2, 1, 0, -1, -2, - 3, or -4 (or any derivable range therein), wherein canonical value is equal to - 3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10]+336051.67*[Linoleic Acid]r,- 19317.97*[glycodeoxycholic acid]r-6074*[miR-92a-3p]r+74219*[miR-25- 3p]r+3248.33*[miR-486-5p]r. The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of sCD14, CRP, VEGF, and IL-10 relative to a control. The subject may be diagnosed138923491.1 - 8 -as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than -3, -4, -5, -6, -7, or -8, wherein the canonical value is equal to - 3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10]. The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and miR-486-5p relative to a control. The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than 0, -0.25, -0.5, -0.75, -1, -1.25, -1.5, -1.75, -2, -2.25, -2.5, -2.75, or 3 (or any derivable range therein), wherein the canonical value is equal to 0.55*[ miR-16-5p]r-1.44*[miR-20a- 5p]r+1.38*[miR-25-3p]r-1.04*[miR-92a-3p]r+0.57*[miR-486-5p]r. The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid relative to a control. The subject may be diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than 0, -0.25, -0.5, -0.75, -1, -1.25, -1.5, -1.75, -2, -2.25, -2.5, -2.75, or 3, wherein the canonical value is equal to -1248.41*[oleoyl-sn-glycero-3- phosphoethanolamine]r-17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r.

[0019] The subject has been evaluated for levels of or the evaluated biomarkers may comprise or consist of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy-3-oxo-4-cholestenoic acid. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a- hydroxy-3-oxo-4-cholestenoic acid relative to a control. The subject may be diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any derivable range therein), wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4-cholestenoic acid] + 0.07. The subject may be diagnosed as not having CA when a biological sample from the subject has been evaluated as not having differential levels of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a- hydroxy-3-oxo-4-cholestenoic acid relative to a control. The subject may be diagnosed as not138923491.1 - 9 -having CA when a biological sample from the subject has been evaluated as having a canonical value of less than -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any derivable range therein), wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4-cholestenoic acid] + 0.07.

[0020] The canonical value may be determined to be greater than -10, -9, -8, -7, -6, -5, -4, - 3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 (or any range derivable therein). The canonical value is determined to be less than -10, -9, -8, -7, -6, -5, -4, - 3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 (or any range derivable therein). The biomarker or metabolite may be determined to have differential levels relative to a control. The biomarker or metabolite may be determined to have or evaluated as having levels not significantly different than a control. The biomarker or metabolite may be determined to be or evaluated as being increased relative to a control. The biomarker or metabolite may be determined to be or evaluated as being decreased relative to a control. The biomarker or metabolite may be evaluated or determined as having differential levels relative to a control. The biomarker or metabolite may be evaluated as having levels not significantly different than a control.

[0021] The subject may be one that has been diagnosed with CA. The subject may be one that has not been diagnosed with CA. The CA may be further defined as CA with symptomatic hemorrhage (CASH). The CA is further defined as CA without symptomatic hemorrhage (non- CASH). The CA may be further defined as non-aggressive CA. The CA may be further defined as aggressive CA. CA may be further defined as familial CA or sporadic CA. Familial CA may be further define as familial-CCM1. Familial CA may be further define as familial-CCM3. The subject may be one that is being treated with a therapy for CA. The subject may be one is not being treated with a therapy for CA.

[0022] The sample from the subject may comprise a tissue sample, a blood sample, a whole blood sample, a fractionated sample, a plasma sample, a fecal sample, or a urine sample. The sample from the subject may comprise a plasma sample from the subject. The methods may exclude detection or determination of any other biomarkers in the sample. The control may comprise the level of the metabolite or biomarker in samples from subjects identified as non- CASH, low risk, as not having CA, or as having non-aggressive CA. The control may comprise138923491.1 - 10 -the expression or protein level of the biomarker in samples from subjects identified as CASH, high risk, as having CA, or as having aggressive CA. The control may comprise the level of the metabolite or biomarker in samples from subjects identified as having non-CASH, in subject identified as low risk, in subjects identified as not having CA, subject identified as having non-aggressive CA, or in subjects having familial CA. The control may comprise the expression or protein level of the biomarker in samples from subjects identified as high risk, in subject identified as having CASH, in subjects identified as having CA, in subject identified as having aggressive CA, or in subjects identified as having sporadic CA. The treatment may comprise a gene therapy, a B-cell immunomodulation therapy, surgical excision of a CCM lesion, or combinations thereof.

[0023] In some aspects, the subject may be one that has been determined to have a canonical value equal to, greater than, less than, at most, or at least -300, -299, -298, -297, - 296, -295, -294, -293, -292, -291, -290, -289, -288, -287, -286, -285, -284, -283, -282, -281, - 280, -279, -278, -277, -276, -275, -274, -273, -272, -271, -270, -269, -268, -267, -266, -265, - 264, -263, -262, -261, -260, -259, -258, -257, -256, -255, -254, -253, -252, -251, -250, -249, - 248, -247, -246, -245, -244, -243, -242, -241, -240, -239, -238, -237, -236, -235, -234, -233, - 232, -231, -230, -229, -228, -227, -226, -225, -224, -223, -222, -221, -220, -219, -218, -217, - 216, -215, -214, -213, -212, -211, -210, -209, -208, -207, -206, -205, -204, -203, -202, -201, - 200, -199, -198, -197, -196, -195, -194, -193, -192, -191, -190, -189, -188, -187, -186, -185, - 184, -183, -182, -181, -180, -179, -178, -177, -176, -175, -174, -173, -172, -171, -170, -169, - 168, -167, -166, -165, -164, -163, -162, -161, -160, -159, -158, -157, -156, -155, -154, -153, - 152, -151, -150, -149, -148, -147, -146, -145, -144, -143, -142, -141, -140, -139, -138, -137, - 136, -135, -134, -133, -132, -131, -130, -129, -128, -127, -126, -125, -124, -123, -122, -121, - 120, -119, -118, -117, -116, -115, -114, -113, -112, -111, -110, -109, -108, -107, -106, -105, - 104, -103, -102, -101, -100, -99, -98, -97, -96, -95, -94, -93, -92, -91, -90, -89, -88, -87, -86, - 85, -84, -83, -82, -81, -80, -79, -78, -77, -76, -75, -74, -73, -72, -71, -70, -69, -68, -67, -66, -65, -64, -63, -62, -61, -60, -59, -58, -57, -56, -55, -54, -53, -52, -51, -50, -49, -48, -47, -46, -45, - 44, -43, -42, -41, -40, -39, -38, -37, -36, -35, -34, -33, -32, -31, -30, -29, -28, -27, -26, -25, -24, -23, -22, -21, -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101,138923491.1 - 11 -102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700 or any derivable range therein.138923491.1 - 12 -

[0024] In some aspects, the canonical value is determined to be equal to, greater than, less than, at most, or at least -300, -299, -298, -297, -296, -295, -294, -293, -292, -291, -290, -289, -288, -287, -286, -285, -284, -283, -282, -281, -280, -279, -278, -277, -276, -275, -274, -273, - 272, -271, -270, -269, -268, -267, -266, -265, -264, -263, -262, -261, -260, -259, -258, -257, - 256, -255, -254, -253, -252, -251, -250, -249, -248, -247, -246, -245, -244, -243, -242, -241, - 240, -239, -238, -237, -236, -235, -234, -233, -232, -231, -230, -229, -228, -227, -226, -225, - 224, -223, -222, -221, -220, -219, -218, -217, -216, -215, -214, -213, -212, -211, -210, -209, - 208, -207, -206, -205, -204, -203, -202, -201, -200, -199, -198, -197, -196, -195, -194, -193, - 192, -191, -190, -189, -188, -187, -186, -185, -184, -183, -182, -181, -180, -179, -178, -177, - 176, -175, -174, -173, -172, -171, -170, -169, -168, -167, -166, -165, -164, -163, -162, -161, - 160, -159, -158, -157, -156, -155, -154, -153, -152, -151, -150, -149, -148, -147, -146, -145, - 144, -143, -142, -141, -140, -139, -138, -137, -136, -135, -134, -133, -132, -131, -130, -129, - 128, -127, -126, -125, -124, -123, -122, -121, -120, -119, -118, -117, -116, -115, -114, -113, - 112, -111, -110, -109, -108, -107, -106, -105, -104, -103, -102, -101, -100, -99, -98, -97, -96, - 95, -94, -93, -92, -91, -90, -89, -88, -87, -86, -85, -84, -83, -82, -81, -80, -79, -78, -77, -76, -75, -74, -73, -72, -71, -70, -69, -68, -67, -66, -65, -64, -63, -62, -61, -60, -59, -58, -57, -56, -55, - 54, -53, -52, -51, -50, -49, -48, -47, -46, -45, -44, -43, -42, -41, -40, -39, -38, -37, -36, -35, -34, -33, -32, -31, -30, -29, -28, -27, -26, -25, -24, -23, -22, -21, -20, -19, -18, -17, -16, -15, -14, - 13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320,138923491.1 - 13 -321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700 or any derivable range therein. In some aspects, the canonical value is determined, measured, or evaluated as greater than 0. In some aspects, the canonical value is determined, measured, or evaluated as less than 0.

[0025] The subject may be diagnosed as having CA, diagnosed as not having CA, diagnosed as having CASH, diagnosed as non-CASH, prognosed at high risk for CA, prognosed at low risk for CA, prognosed as high risk for CASH, prognosed as low risk for CASH, prognosed as high risk for aggressive CA, prognosed as low risk for aggressive CA, diagnosed as having familial CA, or diagnosed as having sporadic CA when the canonical value is determined to be equal to, greater than, less than, at most, or at least -300, -299, -298, -297, -296, -295, -294, - 293, -292, -291, -290, -289, -288, -287, -286, -285, -284, -283, -282, -281, -280, -279, -278, - 277, -276, -275, -274, -273, -272, -271, -270, -269, -268, -267, -266, -265, -264, -263, -262, - 261, -260, -259, -258, -257, -256, -255, -254, -253, -252, -251, -250, -249, -248, -247, -246, - 245, -244, -243, -242, -241, -240, -239, -238, -237, -236, -235, -234, -233, -232, -231, -230, -138923491.1 - 14 -229, -228, -227, -226, -225, -224, -223, -222, -221, -220, -219, -218, -217, -216, -215, -214, - 213, -212, -211, -210, -209, -208, -207, -206, -205, -204, -203, -202, -201, -200, -199, -198, - 197, -196, -195, -194, -193, -192, -191, -190, -189, -188, -187, -186, -185, -184, -183, -182, - 181, -180, -179, -178, -177, -176, -175, -174, -173, -172, -171, -170, -169, -168, -167, -166, - 165, -164, -163, -162, -161, -160, -159, -158, -157, -156, -155, -154, -153, -152, -151, -150, - 149, -148, -147, -146, -145, -144, -143, -142, -141, -140, -139, -138, -137, -136, -135, -134, - 133, -132, -131, -130, -129, -128, -127, -126, -125, -124, -123, -122, -121, -120, -119, -118, - 117, -116, -115, -114, -113, -112, -111, -110, -109, -108, -107, -106, -105, -104, -103, -102, - 101, -100, -99, -98, -97, -96, -95, -94, -93, -92, -91, -90, -89, -88, -87, -86, -85, -84, -83, -82, - 81, -80, -79, -78, -77, -76, -75, -74, -73, -72, -71, -70, -69, -68, -67, -66, -65, -64, -63, -62, -61, -60, -59, -58, -57, -56, -55, -54, -53, -52, -51, -50, -49, -48, -47, -46, -45, -44, -43, -42, -41, - 40, -39, -38, -37, -36, -35, -34, -33, -32, -31, -30, -29, -28, -27, -26, -25, -24, -23, -22, -21, -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428,138923491.1 - 15 -429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700 or any derivable range therein. The subject may be diagnosed as having CA, diagnosed as not having CA, diagnosed as having CASH, diagnosed as non-CASH, prognosed at high risk for CA, prognosed at low risk for CA, prognosed as high risk for CASH, prognosed as low risk for CASH, prognosed as high risk for aggressive CA, prognosed as low risk for aggressive CA, diagnosed as having familial CA, or diagnosed as having sporadic CA when the canonical value is determined to be greater than 0. The subject may be diagnosed as having CA, diagnosed as not having CA, diagnosed as having CASH, diagnosed as non-CASH, prognosed at high risk for CA, prognosed at low risk for CA, prognosed as high risk for CASH, prognosed as low risk for CASH, prognosed as high risk for aggressive CA, prognosed as low risk for aggressive CA, diagnosed as having familial CA, or diagnosed as having sporadic CA when the canonical value is determined to be less than 0.

[0026] The difference in the level of a biomarker or metabolite from a control may be, for example, a statistically significant difference. In some aspects, the difference is at least 0.5, 1, 1.5, 2, 2.5, or 3 standard deviations different than a control. The level may be a difference that is not significantly or statistically different than a control or that is within 2, 1.5, 1, or 0.5 standard deviations from a control. The biomarker or metabolite may be determined or measured as increased relative to a control. The increase may be by at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, or 400% or by at least 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 10, 20, 50, 100 fold. The biomarker or metabolite may be determined or138923491.1 - 16 -measured as decreased relative to a control. The decrease may be by at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, or 400% or by at least 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 10, 20, 50, 100 fold.

[0027] In some aspects, the control comprises the level of the metabolite or biomarker in samples from subjects identified as low risk. In some aspects, the control comprises the level of the metabolite or biomarker in samples from subjects identified as non-CASH. In some aspects, the control comprises the level of the metabolite or biomarker in samples from subjects identified as CASH. In some aspects, the control comprises the level of the metabolite or biomarker in samples from subjects identified as high risk. In some aspects, the control comprises the level of the metabolite or biomarker in samples from subjects identified as not having CA. In some aspects, the control comprises the level of the metabolite or biomarker in samples from subjects identified as having CA. In some aspects, the control comprises the level of the metabolite or biomarker in samples from subjects identified as having non- aggressive CA. In some aspects, the control comprises the level of the metabolite or biomarker in samples from subjects identified as having aggressive CA.

[0028] The subject may be one that has been diagnosed with CA. In some aspects, the subject has not been diagnosed with CA. The CA may be further defined as CASH. The CA may be further defined as non-CASH. The CA may be further defined as aggressive CA. The CA may be further defined as non-aggressive CA. In some aspects, CA is further defined as familial CA or sporadic CA. In some aspects, familial CA is further define as familial-CCM1. In some aspects, familial CA is further define as familial-CCM3. The subject may be one that is being treated with a therapy for CA. In some aspects, the subject is not being treated with a therapy for CA. In some aspects, the methods comprise or further comprise administering a therapy for CA. The therapy may comprise or consist of a gene therapy, a B-cell immunomodulation therapy, surgical excision of a CCM lesion, or combinations thereof. The therapy may also exclude one or more of a gene therapy, a B-cell immunomodulation therapy, and surgical excision of a CCM lesion.

[0029] The biological sample from the subject may comprise a tissue sample, a blood sample, a whole blood sample, a fractionated sample, a plasma sample, a fecal sample, or a urine sample. In some aspects, the biological sample from the subject comprises a plasma sample from the subject. In some aspects, the biological sample from the subject comprises a sample type described herein.138923491.1 - 17 -

[0030] In some aspects, the subject may be one that has been determined to have a canonical value, or the methods comprise determining a canonical value that is equal to, greater than, less than, at most, or at least -10, -9.8, -9.6, -9.4, -9.2, -9, -8.8, -8.6, -8.4, -8.2, -8, -7.8, -7.6, -7.4, - 7.2, -7, -6.8, -6.6, -6.4, -6.2, -6, -5.8, -5.6, -5.4, -5.2, -5, -4.8, -4.6, -4.4, -4.2, -4, -3.8, -3.6, -3.4, -3.2, -3, -2.8, -2.6, -2.4, -2.2, -2, -1.8, -1.6, -1.4, -1.2, -1, -0.8, -0.6, -0.4, -0.2, 0, 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8, 3, 3.2, 3.4, 3.6, 3.8, 4, 4.2, 4.4, 4.6, 4.8, 5, 5.2, 5.4, 5.6, 5.8, 6, 6.2, 6.4, 6.6, 6.8, 7, 7.2, 7.4, 7.6, 7.8, 8, 8.2, 8.4, 8.6, 8.8, 9, 9.2, 9.4, 9.6, 9.8, 10, 10.2, 10.4, 10.6, 10.8, 11, 11.2, 11.4, 11.6, 11.8, 12, 12.2, 12.4, 12.6, 12.8, 13, 13.2, 13.4, 13.6, 13.8, 14, 14.2, 14.4, 14.6, 14.8, 15, 15.2, 15.4, 15.6, 15.8, 16, 16.2, 16.4, 16.6, 16.8, 17, 17.2, 17.4, 17.6, 17.8, 18, 18.2, 18.4, 18.6, 18.8, 19, 19.2, 19.4, 19.6, 19.8, 20, 20.2, 20.4, 20.6, 20.8, 21, 21.2, 21.4, 21.6, 21.8, 22, 22.2, 22.4, 22.6, 22.8, 23, 23.2, 23.4, 23.6, 23.8, 24, 24.2, 24.4, 24.6, 24.8, 25, 25.2, 25.4, 25.6, 25.8, 26, 26.2, 26.4, 26.6, 26.8, 27, 27.2, 27.4, 27.6, 27.8, 28, 28.2, 28.4, 28.6, 28.8, 29, 29.2, 29.4, 29.6, 29.8, 30, 30.2, 30.4, 30.6, 30.8, 31, 31.2, 31.4, 31.6, 31.8, 32, 32.2, 32.4, 32.6, 32.8, 33, 33.2, 33.4, 33.6, 33.8, 34, 34.2, 34.4, 34.6, 34.8, 35, or any range derivable therein.

[0031] Methods for measuring metabolites are known in the art. For example, the metabolites may be measured by liquid chromatography, mass spectrometry, and / or tandem mass spectrometry. Data analyses can be performed using a complete a lock mass correction using hexakis (1H, 1H, 2H-difluoroethoxy) phosphazene (Synquest Laboratories, Alachua, FL) implemented within the Bruker Data Analysis Software. Feature detection can be done with the open-source software MZmine v2.38 [Pluskal]. The unsupervised, differential metabolome between (1) CA and non-CA, (2) CASH and non-CASH, (3) aggressive and non- aggressive, as well as (4) familial and sporadic CA can be performed with PLS-Discriminant Analysis (PLS-DA,) using the R Software. A random permutations analysis on the peak values of the differentially expressed metabolite can be performed to estimate the significance of the computed PLS-DA coefficients. Normalized plasma concentrations of each metabolite can be calculated for each patient. Methods for measuring protein levels are known in the art. Protein concentrations can be determined using enzyme-linked immunosorbent assay (ELISA) assays or multiplex electrochemiluminescence immunoassays.

[0032] The kits of the disclosure may comprise, comprise at least, or comprise at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79,138923491.1 - 18 -80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 (or any derivable range therein) detection agents for detecting one or more metabolites and / or biomarkers. The detection agents may comprise antibodies, nucleic acid probes, or peptides that are useful for detecting the metabolites and / or biomarkers. Kit embodiments of the disclosure may comprise one or more negative or positive control samples and / or control detection agents. The kit may comprise or further comprise instructions for use.

[0033] The kit may comprise one or more negative or positive control samples and / or control detection agents. The kit may comprise instructions for use. The biomarkers or metabolites may comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a- 5p, mir-25-3p, and / or miR-486-5p. The biomarkers or metabolites may comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, miR-486-5p, and / or one or more control(s). The instructions may comprise evaluating a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL- 10]+316.54*[Linoleic Acid]r,-6.06*[miR-20a-5p]r+5.41*[mir-25-3p]r+1.26*[miR-486-5p]r.

[0034] The biomarkers or metabolites may comprise or consist of sCD14, CRP, VEGF, IL- 10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, and / or miR-486-5p. The biomarkers or metabolites may comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, miR-486-5p, and / or one or more control(s). The instructions may comprise evaluating a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL- 10]+336051.67*[Linoleic Acid]r,-19317.97*[glycodeoxycholic acid]r-6074*[miR-92a- 3p]r+74219*[miR-25-3p]r+3248.33*[miR-486-5p]r.

[0035] The biomarkers or metabolites may comprise or consist of sCD14, CRP, VEGF, and / or IL-10. The biomarkers or metabolites may comprise or consist of sCD14, CRP, VEGF, IL-10, and / or one or more control(s). The instructions may comprise evaluating a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]- 0.57*[IL-10].

[0036] The biomarkers or metabolites may comprise or consist of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and / or miR-486-5p.

[0037] The biomarkers or metabolites may comprise or consist of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, miR-486-5p, and / or one or more control(s). The instructions may138923491.1 - 19 -comprise evaluating a canonical value, wherein the canonical value is equal to 0.55*[ miR-16- 5p]r-1.44*[miR-20a-5p]r+1.38*[miR-25-3p]r-1.04*[miR-92a-3p]r+0.57*[miR-486-5p]r.

[0038] The biomarkers or metabolites may comprise or consist of oleoyl-sn-glycero-3- phosphoethanolamine, glycodeoxycholic acid, and / or linoleic acid. The biomarkers or metabolites may comprise or consist of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, linoleic acid, and / or one or more control(s). The instructions may comprise evaluating a canonical value, wherein the canonical value is equal to - 1248.41*[oleoyl-sn-glycero-3-phosphoethanolamine]r-17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r.

[0039] The biomarkers or metabolites may comprise or consist of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and / or 7a-hydroxy-3-oxo-4-cholestenoic acid. The biomarkers or metabolites may comprise or consist of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, 7a-hydroxy-3-oxo-4-cholestenoic acid, and / or one or more control(s). The instructions may comprise evaluating a canonical value, wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4-cholestenoic acid] + 0.07.

[0040] The biomarkers or metabolites may comprise or consist of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, and / or bilirubin. The biomarkers or metabolites may comprise or consist of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3- phosphocholine, bilirubin, and / or one or more control(s). The instructions may comprise evaluating a canonical value, wherein the canonical value is equal to 3682.02 * [cis-9- hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn-glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.48.

[0041] The biomarkers or metabolites may comprise or consist of decanoyl-L-carnitine. The biomarkers or metabolites may comprise or consist of decanoyl-L-carnitine and one or more control(s). The instructions may comprise evaluating a canonical value, wherein the canonical value is equal to 1236.91 * [decanoyl-L-carnitine] – 0.37.

[0042] The kits may comprise reagents for isolation and / or amplification of biomarkers and / or metabolites from a biological sample. The kit may exclude reagents for detection of any other biomarkers or metabolites.138923491.1 - 20 -

[0043] The kit may comprise reagents for isolation and / or amplification of biomarkers and / or metabolites from a biological sample. The biological sample may be a sample from a subject. In some aspects, the kit may excludes reagents for detection of any other biomarkers or metabolites.

[0044] The subject may be a mammal. In some aspects, the subject comprises a laboratory test animal, such as a mouse, rat, rabbit, dog, cat, horse, or pig. In some aspects, the subject is a human. In some aspects, the subject is a human patient.

[0045] “Treatment” or treating may refer to any treatment of a disease in a mammal, including: (i) preventing the disease, that is, causing the clinical symptoms of the disease not to develop by administration of a protective composition prior to the induction of the disease; (ii) suppressing the disease, that is, causing the clinical symptoms of the disease not to develop by administration of a protective composition after the inductive event but prior to the clinical appearance or reappearance of the disease; (iii) inhibiting the disease, that is, arresting the development of clinical symptoms by administration of a protective composition after their initial appearance; and / or (iv) relieving the disease, that is, causing the regression of clinical symptoms by administration of a protective composition after their initial appearance. In some aspects, the treatment may exclude prevention of the disease.

[0046] Throughout this application, the term “about” is used according to its plain and ordinary meaning in the area of cell and molecular biology to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0047] The use of the word “a” or “an” when used in conjunction with the term “comprising” may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

[0048] As used herein, the terms “or” and “and / or” are utilized to describe multiple components in combination or exclusive of one another. For example, “x, y, and / or z” can refer to “x” alone, “y” alone, “z” alone, “x, y, and z,” “(x and y) or z,” “x or (y and z),” or “x or y or z.” It is specifically contemplated that x, y, or z may be specifically excluded from an embodiment or aspect.

[0049] The words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), “characterized by” (and any form of including, such as “characterized as”), or “containing” (and any form of containing, such as138923491.1 - 21 -“contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0050] The compositions and methods for their use can “comprise,” “consist essentially of,” or “consist of” any of the ingredients or steps disclosed throughout the specification. The phrase “consisting of” excludes any element, step, or ingredient not specified. The phrase “consisting essentially of” limits the scope of described subject matter to the specified materials or steps and those that do not materially affect its basic and novel characteristics. It is contemplated that embodiments and aspects described in the context of the term “comprising” may also be implemented in the context of the term “consisting of” or “consisting essentially of.”

[0051] Any method in the context of a therapeutic, diagnostic, or physiologic purpose or effect may also be described in “use” claim language such as “Use of” any compound, composition, or agent discussed herein for achieving or implementing a described therapeutic, diagnostic, or physiologic purpose or effect.

[0052] Use of the one or more sequences or compositions may be employed based on any of the methods described herein. Other embodiments are discussed throughout this application. Any embodiment or aspect discussed with respect to one aspect of the disclosure applies to other aspects of the disclosure as well and vice versa.

[0053] It is specifically contemplated that any limitation discussed with respect to one embodiment or aspect of the invention may apply to any other embodiment or aspect of the invention. Furthermore, any composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or to utilize any composition of the invention. Aspects of an embodiment set forth in the Examples are also embodiments that may be implemented in the context of embodiments discussed elsewhere in a different Example or elsewhere in the application, such as in the Summary of Invention, Detailed Description of the Embodiments, Claims, and description of Figure Legends.

[0054] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments and aspects of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.138923491.1 - 22 -BRIEF DESCRIPTION OF THE DRAWINGS

[0055] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0056] FIG. 1A-B: Heatmaps of the differential metabolomic profiles in cavernous angioma (CA) disease and its clinical manifestations. A PLS-Discriminant Analysis showed differences in the plasma levels for (A) 15 metabolites between CA patients (n=53) and healthy non-CA subjects (n=17), (B) four between cavernous angioma with symptomatic hemorrhage (CASH) patients (n=5) and cavernous angioma without symptomatic hemorrhage (non-CASH) patients (n=48) (p<0.05, FDR corrected; Bayes factor>3). Z-scores were calculated to compare metabolite levels across patients within each comparison group, with lower z scores (darker grey) representing lower relative plasma levels of metabolites. Metabolites with listed PubChem IDs are identified in Supp. Tables 2 and 3.

[0057] FIG.2. Integrative analyses of cholic acid and hypoxanthine between the differential microbiome, plasma proteome and lesional transcriptome of cavernous angioma (CA) disease. The plasma levels of cholic acid and hypoxanthine, which were lower in CA patients compared to healthy non-CA subjects (p<0.05, FDR corrected), were later linked to Bifidobacterium adolescentis, Faecalibacterium prausnitzii, and Odoribacter splanchnicus. Further integrative analyses identified nine enriched Kyoto Encyclopedia of Genes and Genomes (KEGG)- pathways (p<0.05, false discovery rate [FDR] corrected; Bayes factor>3) that overlap between the differential plasma proteome and metabolome as well as with the lesional transcriptome of CA disease. Reported to have a role in the physiopathogenesis of CAs, these nine pathways were categorized into six biological processes with pre-established relevance to CA disease.

[0058] FIG.3. Arachidonic acid links Enterobacter cloacae and 11 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched across the differential proteome and transcriptome of cavernous angioma with symptomatic hemorrhage (CASH) patients. The integrative analyses draw a link between higher plasma levels of arachidonic acid and Enterobacter cloacae in CASH patients (p<0.05, false discovery rate [FDR] corrected; Bayes factor>3). Further analyses also identified 11 enriched-KEGG pathways with a role in cavernous angioma (CA) disease that overlapped between the differential plasma metabolome and proteome as well as the lesional transcriptome of CA disease. These 11 pathways were138923491.1 - 23 -then categorized into six biological processes mechanistically related to CA disease (p<0.05, FDR corrected; Bayes factor>3).

[0059] FIG.4A-D. Weighted combinations of plasma ratio of metabolites and micro-RNAs (miRNAs) improve the performance of the proteins-based cavernous angioma with symptomatic hemorrhage (CASH) biomarker. The canonical values estimated with the optimal integrative weighted model were (A) higher (p<0.0001) in the CASH (n=20) compared with cavernous angioma without symptomatic hemorrhage (non-CASH) patients (n=20) included in the independent propensity matched validation cohort. (B) The receiver operating characteristic (ROC) analyses showed that this integrative model differentiated CASH patients from non- CASH patients with 80% sensitivity and 95% specificity (area under the curve [AUC]=90.25%). (C) An alternative optimal integrative weighted model developed using a parallel 10-fold cross validation machine learning approach showed higher canonical values higher (p<0.0001) in CASH compared with non-CASH patients. (D) The ROC analysis showed that the alternative optimal integrative model differentiated CASH from non-CASH with 85% sensitivity and 80% specificity (AUC=90.75%). CI, confidence interval; ***, p<0.001.

[0060] FIG. 5. Methodology for analytic multi-omics integration of differential plasma metabolome and proteome, microbiome and lesional transcriptome, in cavernous angioma (CA) disease. A pipeline was implemented to study the integration of multi-omic datasets of CA disease. The interacting Comparative Toxicogenomics Database (CTD) genes and their associated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of the differential plasma metabolite (p<0.05, FDR corrected; Bayes factor>3) were first identified and then analytically compared to the enriched-KEGG pathways of the differential plasma proteome, and lesional transcriptome (p<0.05, FDR corrected; Bayes factor>3). The differential metabolites were then validated in an independent cohort, propensity matched for age, sex, brainstem lesion, and genotype. NVUs, neurovascular units.

[0061] FIG. 6. Eleven enriched- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways identified in cavernous angioma (CA) patients versus healthy non-CA subjects were common between the differential metabolites, plasma proteome, and lesional transcriptome. The plasma levels of 15 metabolites were different between CA patients and healthy non-CA analysis. Of these 15 metabolites, five were only integrated with KEGG pathways dysregulated in the lesional transcriptome of CA. The overlap analytic comparisons of enriched-KEGG pathways from these differential metabolites and the differential plasma proteome and lesional138923491.1 - 24 -transcriptome identified 11 common pathways (p<0.05, false discovery rate corrected; Bayes factor>3).

[0062] FIG. 7. Nine Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways identified between cavernous angioma with symptomatic hemorrhage (CASH) and cavernous angioma without symptomatic hemorrhage (non-CASH) patients overlapped across differential metabolites, the differential plasma proteome, and lesional transcriptome of cavernous angioma disease. The plasma levels of glycodeoxycholic and linoleic acids were also different between CASH and non-CASH patients. Overlap analyses between these differential metabolites, the plasma proteome, and lesional transcriptome found nine KEGG pathways with CA relevance (p<0.05, false discovery rate corrected; Bayes factor>3).

[0063] FIG. 8A-D. Four metabolites differentially expressed in cavernous angioma with symptomatic hemorrhage (CASH) events were validated in an independent cohort. The receiving operating characteristic analyses showed that the ratio plasma levels of (A) arachidonic acid were able to differentiate CASH patients with 60% sensitivity and 60% specificity (area under the curve [AUC]=57.0%), (B) glycodeoxycholic acid distinguished CASH with 70% sensitivity and 45% specificity (AUC=63.2%), (C)1-oleyl-sn-glycero-3- phosphethanolamine performed with 60% sensitivity and 50% specificity (AUC=59.4%) while (D) linoleic acid showed 55% sensitivity and 80% specificity (AUC=66.8%).

[0064] FIG. 9. Heatmap showing the correlation between plasma protein levels and differential metabolites. Plasma levels of the 19 proteins were correlated with normalized plasma levels of 23 metabolites using Pearson coefficient. The plasma levels of five metabolites were correlated with the plasma levels of five proteins and could implicate biological mechanistic relationships between the molecules. Pubchem ID compound names can be found in Supp. Tables 2, 3, 6, 7. *; p<0.05, false discovery rate corrected

[0065] FIG. 10A-F. Weighted combinations of plasma proteins, metabolites and micro- RNAs (miRNAs) separately to diagnose a cavernous angioma with symptomatic hemorrhage (CASH) event. The canonical values estimated by the best weighted combination with only plasma proteins were higher (A-B) in CASH (n=20) compared to cavernous angioma without symptomatic hemorrhage (non-CASH, n=20) patients (p=0.06) and distinguished these patients with 75% sensitivity and 60% specificity (area under the curve [AUC]=67.5%). Canonical values calculated for the optimal weighted combination of metabolites differentially expressed and validated in CASH were (C) higher in CASH compared to non-CASH patients,138923491.1 - 25 -and (D) distinguished with 85% sensitivity and 60% specificity (AUC=72.3%). Finally, the optimal weighted combination of miRNAs showed (E) higher canonical values in CASH patients and performed with (F) 100% sensitivity and 60% specificity (AUC=85.3%). CI, confidence interval; *, p<0.05, ***, p<0.001.

[0066] FIG. 11A-B. Heatmaps of the differential metabolomic profiles in the clinical manifestations of cavernous angioma (CA) disease. A PLS-Discriminant Analysis showed differences in plasma levels of (A) six metabolites between aggressive (n=19) and non- aggressive (n=34) CA patients. (B) In addition, the plasma levels of three metabolites were different between familial (n=25) and sporadic (n=28) CA patients (all: p<0.05, FDR corrected; Bayes factor>3). Z-scores were calculated to compare metabolite levels across patients within each comparison group, with lower z scores (darker blue) representing lower relative plasma levels of metabolites. Metabolites with listed PubChem IDs are identified in Supp. Tables 6 and 7.

[0067] FIG. 12. Ten enriched- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were identified to overlap between the differential metabolites identified between aggressive and non-aggressive cavernous angioma (CA) patients as well as the differential plasma proteome, and lesional transcriptome. The plasma levels of six metabolites were different between aggressive and non-aggressive CA patients. Ten KEGG pathways with CA relevance were found overlapping across three of the differential metabolites, the plasma proteome, and lesional transcriptome, that were then characterized into six CA biological processes (p<0.05, false discovery rate corrected; Bayes factor>3).

[0068] FIG. 13. Seven Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways overlapped across differential metabolites, the differential plasma proteome, and lesional transcriptome when comparing familial- and sporadic-cavernous angioma (CA) patients. The plasma levels of glycodeoxycholic and glycocholic acids were different between familial-CA and sporadic-CA patients. Seven CA-relevant KEGG pathways overlapped across these two metabolites, the differential plasma proteome, and the lesional transcriptome (p<0.05, false discovery rate corrected; Bayes factor>3).

[0069] FIG. 14. Level 1 Confirmation of Linoleic Acid. A level 1 confirmation was performed to support the results of linoleic acid using predefined standards for 10E, 12Z- Conjugated Linoleic; Rumenic; and Linoleic acids as well as plasma samples. The results138923491.1 - 26 -confirmed that linoleic acid shared the exact fragmentation profile, m / z ratio, and retention time with the molecule identified in the pooled patient samples.

[0070] FIG. 15. Canonical values of Diagnostic Biomarkers using proteins, miRNAs, and / or metabolites. DETAILED DESCRIPTION OF THE INVENTION

[0071] The inventors identified and validated several homologous DE plasma miRNAs with mechanistic links to CCM disease in preclinical murine models and CCM patients. Additionally, they show that the integration of readily measurable plasma proteins and miRNAs into a combined biomarker can diagnose familial-CCM disease with 100% accuracy. To the knowledge of the inventors, such a translational approach to biomarker discovery in mouse models and humans, transcriptomic links, validation in an independent human cohort, and the combination of miRNA and protein levels to optimize biomarker performance have not been previously described in any other disease.

[0072] This study is the first to show a near perfect diagnostic precision with the weighted combination of plasma miRNAs and proteins in a Mendelian disease, based on ML and Bayesian approaches. Two cross-validation methods confirmed that integrating plasma miRNAs and proteins improves the diagnostic association with familial-CCM compared to each circulating compound (e.g., plasma miRNA and protein) alone. This result acts as an important proof of concept for integration of several types of molecules in plasma biomarker development (12). A homologous biomarker in mice and humans, which can differentiate familial-CCM with germline loss of function mutations can be immediately applied in preclinical studies and early trials, monitoring effectiveness of gene restoration therapeutics, which are currently of great interest. As patients undergo gene therapy, one could monitor their progress and the duration of therapeutic effect as biomarker canonical values shift in comparison to a healthy non-CCM profile. This approach to combined biomarker development is readily applicable to other clinical contexts of use, including the prediction of new lesion formation.

[0073] In summary, the inventors have shown for the first time in any disease, that homologous DE plasma miRNAs can reflect the germline loss of function mutation in preclinical murine models and patients. They have also shown that plasma miRNAs can distinguish cases who would develop new lesions and can be assayed in peripheral blood. The138923491.1 - 27 -inventors describe a novel approach which can be developed for translatable circulating biomarkers in specific clinical contexts of use in CCM and other Mendelian diseases. II. ROC analysis

[0074] In statistics, a receiver operating characteristic (ROC), or ROC curve, is a graphical plot that illustrates the performance of a binary classifier system as its discrimination threshold is varied. ROC analysis may be applied to determine a cut-off value or threshold setting of biomarker expression, such as the canonical value described herein. For example, patients with biological samples determined to have biomarker expression value above a certain cut-off threshold but below a higher cut-off threshold may be determined to have endometriosis. Patients with biological samples determined to have a biomarker expression level that surpasses the cut-off threshold may be determined to have a disease or condition such as multiple sclerosis. The curve is created by plotting the true positive rate against the false positive rate at various threshold settings. (The true-positive rate is also known as sensitivity in biomedical informatics, or recall in machine learning. The false-positive rate is also known as the fall-out and can be calculated as 1 - specificity). The ROC curve is thus the sensitivity as a function of fall-out. In general, if the probability distributions for both detection and false alarm are known, the ROC curve can be generated by plotting the cumulative distribution function (area under the probability distribution from –infinity to + infinity) of the detection probability in the y-axis versus the cumulative distribution function of the false-alarm probability in x-axis.

[0075] ROC analysis provides tools to select possibly optimal models and to discard suboptimal ones independently from (and prior to specifying) the cost context or the class distribution. ROC analysis is related in a direct and natural way to cost / benefit analysis of diagnostic decision making.

[0076] The ROC curve was first developed by electrical engineers and radar engineers during World War II for detecting enemy objects in battlefields and was soon introduced to psychology to account for perceptual detection of stimuli. ROC analysis since then has been used in medicine, radiology, biometrics, and other areas for many decades and is increasingly used in machine learning and data mining research.

[0077] The ROC is also known as a relative operating characteristic curve, because it is a comparison of two operating characteristics (TPR and FPR) as the criterion changes. ROC analysis curves are known in the art and described in Metz CE (1978) Basic principles of ROC138923491.1 - 28 -analysis. Seminars in Nuclear Medicine 8:283-298; Youden WJ (1950) An index for rating diagnostic tests. Cancer 3:32-35; Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical Chemistry 39:561-577; and Greiner M, Pfeiffer D, Smith RD (2000) Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Preventive Veterinary Medicine 45:23-41, which are herein incorporated by reference in their entirety. A ROC analysis may be used to create cut-off values for prognosis and / or diagnosis purposes. III. Gene and RNA Expression Levels

[0078] Methods disclosed herein include measuring expression of genes and / or RNAs (RNAs) such as messenger RNAs (mRNAs), micro RNAs (miRNAs) and noncoding RNAs (ncRNAs). Measurement of expression can be done by a number of processes known in the art. The process of measuring expression may begin by extracting RNA from a metastasis tissue sample. Extracted mRNA and / or ncRNA can be detected by hybridization (for example by means of Northern blot analysis or DNA or RNA arrays (microarrays) after converting RNA into labeled cDNA) and / or amplification by means of a enzymatic chain reaction. Quantitative or semi-quantitative enzymatic amplification methods such as polymerase chain reaction (PCR) or quantitative real-time RT-PCR or semi-quantitative RT-PCR techniques can be used. Suitable primers for amplification methods encompassed herein can be readily designed by a person skilled in the art. Other amplification methods include ligase chain reaction (LCR), transcription-mediated amplification (TMA), strand displacement amplification (SDA), isothermal amplification of nucleic acids, and nucleic acid sequence based amplification (NASBA). Expression levels of mRNAs and / or ncRNAs may also be measured by RNA sequencing methods known in the art. RNA sequencing methods may include mRNA-seq, total RNA-seq, targeted RNA-seq, small RNA-seq, single-cell RNA-seq, ultra-low-input RNA-seq, RNA exome capture sequencing, and ribosome profiling. Sequencing data may be processed an aligned using methods known in the art.

[0079] To normalize the expression values of one gene among different samples, comparing the mRNA and / or ncRNA level of interest in the samples from the subject object of study with a control RNA level is possible. As it is used herein, a "control RNA" is an RNA of a gene for which the expression level does not differ among different metastatic subtypes, for example a gene that is constitutively expressed in all types of cells. A control RNA is preferably an mRNA derived from a housekeeping gene encoding a protein that is constitutively expressed and carrying out essential cell functions. A known amount of a control RNA may be added to138923491.1 - 29 -the sample(s) and the value measured for the level of the RNA of interest may be normalized to the value measured for the known amount of the control RNA. Normalization for some methods, such as for sequencing, may comprise calculating the reads per kilobase of transcript per million mapped reads (RPKM) for a gene of interest, or may comprise calculating the fragments per kilobase of transcript per million mapped reads (FPKM) for a gene of interest. Normalization methods may comprise calculating the log2-transformed count per million (log- CPM). It can be appreciated to one skilled in the art that any method of normalization that accurately calculates the expression value of an RNA for comparison between samples may be used.

[0080] Methods disclosed herein may include comparing a measured expression level to a reference expression level. The term "reference expression level" refers to a value used as a reference for the values / data obtained from samples obtained from patients. The reference level can be an absolute value, a relative value, a value which has an upper and / or lower limit, a series of values, an average value, a median, a mean value, or a value expressed by reference to a control or reference value. A reference level can be based on the value obtained from an individual sample, such as, for example, a value obtained from a sample from the subject object of study but obtained at a previous point in time. The reference level can be based on a high number of samples, such as the levels obtained in a cohort of subjects having a particular characteristic. The reference level may be defined as the mean level of the patients in the cohort. For example, the reference expression level for a gene or RNA can be based on the mean expression level of the gene or RNA obtained from a number of patients who have SNF2 metastases. A reference level can be based on the expression levels of the markers to be compared obtained from samples from subjects who do not have a disease state or a particular phenotype. The person skilled in the art will see that the particular reference expression level can vary depending on the specific method to be performed.

[0081] Some embodiments include determining that a measured expression level is higher than, lower than, increased relative to, decreased relative to, equal to, or within a predetermined amount of a reference expression level. In some embodiments, a higher, lower, increased, or decreased expression level is at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 50, 100, 150, 200, 250, 500, or 1000 fold (or any derivable range therein) or at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, or 900% different than the reference level, or any derivable range therein. These values may represent a predetermined threshold level, and some embodiments include determining that the measured138923491.1 - 30 -expression level is higher by a predetermined amount or lower by a predetermined amount than a reference level. In some embodiments, a level of expression may be qualified as “low” or “high,” which indicates the patient expresses a certain gene or RNA at a level relative to a reference level or a level with a range of reference levels that are determined from multiple samples meeting particular criteria. The level or range of levels in multiple control samples is an example of this. In some embodiments, that certain level or a predetermined threshold value is at, below, or above 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percentile, or any range derivable therein. Moreover, a threshold level may be derived from a cohort of individuals meeting a particular criteria. The number in the cohort may be, be at least, or be at most 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 or more (or any range derivable therein). A measured expression level can be considered equal to a reference expression level if it is within a certain amount of the reference expression level, and such amount may be an amount that is predetermined. This can be the case, for example, when a classifier is used to identify the molecular subtype of a metastasis. The predetermined amount may be within 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50% of the reference level, or any range derivable therein.

[0082] For any comparison of gene and / or RNA expression levels to a mean expression levels or a reference expression levels, the comparison is to be made on a gene-by-gene and RNA-by-RNA basis. For example, if the expression levels of gene A, gene B, and miRNA X in a patient’s metastasis are measured, a comparison to mean expression levels in metastases of a cohort of patients would involve: comparing the expression level of gene A in the patient’s metastasis with the mean expression level of gene A in metastases of the cohort of patients, comparing the expression level of gene B in the patient’s metastasis with the mean expression level of gene B in metastases of the cohort of patients, and comparing the expression level of RNA X in the patient’s metastasis with the mean expression level of RNA X in metastases of the cohort of patients. Comparisons that involve determining whether the expression level138923491.1 - 31 -measured in a patient’s metastasis is within a predetermined amount of a mean expression level or reference expression level are similarly done on a gene-by-gene and ncRNA-by-ncRNA basis, as applicable. IV. Protein Assays

[0083] A variety of techniques can be employed to measure expression levels of polypeptides and proteins in a biological sample to determine biomarker expression levels. Examples of such formats include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA). A skilled artisan can readily adapt known protein / antibody detection methods for use in determining protein expression levels of biomarkers.

[0084] In one embodiment, antibodies, or antibody fragments or derivatives, can be used in methods such as Western blots, ELISA, or immunofluorescence techniques to detect biomarker expression. In some embodiments, either the antibodies or proteins are immobilized on a solid support. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

[0085] One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present disclosure. The support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means.

[0086] Immunohistochemistry methods are also suitable for detecting the expression levels of biomarkers. In some embodiments, antibodies or antisera, including polyclonal antisera, and monoclonal antibodies specific for each marker may be used to detect expression. The antibodies can be detected by direct labeling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horseradish peroxidase or alkaline phosphatase. Alternatively, unlabeled primary antibody is used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody. Immunohistochemistry protocols and kits are well known in the art and are commercially available.138923491.1 - 32 -

[0087] Immunological methods for detecting and measuring complex formation as a measure of protein expression using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), fluorescence-activated cell sorting (FACS) and antibody arrays. Such immunoassays typically involve the measurement of complex formation between the protein and its specific antibody. These assays and their quantitation against purified, labeled standards are well known in the art. A two-site, monoclonal-based immunoassay utilizing antibodies reactive to two non-interfering epitopes or a competitive binding assay may be employed.

[0088] Numerous labels are available and commonly known in the art. Radioisotope labels include, for example, 36S, 14C, 125I, 3H, and 131I. The antibody can be labeled with the radioisotope using the techniques known in the art. Fluorescent labels include, for example, labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin and Texas Red are available. The fluorescent labels can be conjugated to the antibody variant using the techniques known in the art. Fluorescence can be quantified using a fluorimeter. Various enzyme-substrate labels are available and U.S. Pat. Nos.4,275,149, 4,318,980 provides a review of some of these. The enzyme generally catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, .beta.-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O'Sullivan et al., Methods for the Preparation of Enzyme-Antibody Conjugates for Use in Enzyme Immunoassay, in138923491.1 - 33 -Methods in Enzymology (Ed. J. Langone & H. Van Vunakis), Academic press, New York, 73: 147-166 (1981).

[0089] In some embodiments, a detection label is indirectly conjugated with an antibody. The skilled artisan will be aware of various techniques for achieving this. For example, the antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody is conjugated with a small hapten (e.g., digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g., anti-digoxin antibody). In some embodiments, the antibody need not be labeled, and the presence thereof can be detected using a labeled antibody, which binds to the antibody. V. Sample Preparation

[0090] In certain aspects, methods involve obtaining a sample from a subject. The methods of obtaining provided herein may include methods of biopsy such as fine needle aspiration, core needle biopsy, vacuum assisted biopsy, incisional biopsy, excisional biopsy, punch biopsy, shave biopsy or skin biopsy. The sample may be obtained from any source including but not limited to blood, serum, plasma, sweat, hair follicle, buccal tissue, tears, menses, feces, or saliva. In certain aspects of the current methods, any medical professional such as a doctor, nurse or medical technician may obtain a biological sample for testing. Yet further, the biological sample can be obtained without the assistance of a medical professional.

[0091] A sample may include but is not limited to, tissue, cells, or biological material from cells or derived from cells of a subject. The biological sample may be a heterogeneous or homogeneous population of cells or tissues. The biological sample may be obtained using any method known to the art that can provide a sample suitable for the analytical methods described herein. The sample may be obtained by non-invasive methods including but not limited to: scraping of the skin or cervix, swabbing of the cheek, saliva collection, urine collection, feces collection, collection of menses, tears, or semen.

[0092] The sample may be obtained by methods known in the art. In certain embodiments the samples are obtained by biopsy. In other embodiments the sample is obtained by swabbing, endoscopy, scraping, phlebotomy, or any other methods known in the art. In some cases, the sample may be obtained, stored, or transported using components of a kit of the present138923491.1 - 34 -methods. In some cases, multiple samples, such as multiple plasma or serum samples may be obtained for diagnosis by the methods described herein. In other cases, multiple samples, such as one or more samples from one tissue type (for example ovaries or related tissues) and one or more samples from another specimen (for example serum) may be obtained for diagnosis by the methods. Samples may be obtained at different times are stored and / or analyzed by different methods. For example, a sample may be obtained and analyzed by routine staining methods or any other cytological analysis methods.

[0093] In some embodiments the biological sample may be obtained by a physician, nurse, or other medical professional such as a medical technician, endocrinologist, cytologist, phlebotomist, radiologist, or a pulmonologist. The medical professional may indicate the appropriate test or assay to perform on the sample. In certain aspects a molecular profiling business may consult on which assays or tests are most appropriately indicated. In further aspects of the current methods, the patient or subject may obtain a biological sample for testing without the assistance of a medical professional, such as obtaining a whole blood sample, a urine sample, a fecal sample, a buccal sample, or a saliva sample.

[0094] In other cases, the sample is obtained by an invasive procedure including but not limited to: biopsy, needle aspiration, blood draw, endoscopy, or phlebotomy. The method of needle aspiration may further include fine needle aspiration, core needle biopsy, vacuum assisted biopsy, or large core biopsy. In some embodiments, multiple samples may be obtained by the methods herein to ensure a sufficient amount of biological material.

[0095] General methods for obtaining biological samples are also known in the art. Publications such as Ramzy, Ibrahim Clinical Cytopathology and Aspiration Biopsy 2001, which is herein incorporated by reference in its entirety, describes general methods for biopsy and cytological methods.

[0096] In some embodiments of the present methods, the molecular profiling business may obtain the biological sample from a subject directly, from a medical professional, from a third party, or from a kit provided by a molecular profiling business or a third party. In some cases, the biological sample may be obtained by the molecular profiling business after the subject, a medical professional, or a third party acquires and sends the biological sample to the molecular profiling business. In some cases, the molecular profiling business may provide suitable containers, and excipients for storage and transport of the biological sample to the molecular profiling business.138923491.1 - 35 -

[0097] In some embodiments of the methods described herein, a medical professional need not be involved in the initial diagnosis or sample acquisition. An individual may alternatively obtain a sample through the use of an over the counter (OTC) kit. An OTC kit may contain a means for obtaining said sample as described herein, a means for storing said sample for inspection, and instructions for proper use of the kit. In some cases, molecular profiling services are included in the price for purchase of the kit. In other cases, the molecular profiling services are billed separately. A sample suitable for use by the molecular profiling business may be any material containing tissues, cells, nucleic acids, genes, gene fragments, expression products, gene expression products, or gene expression product fragments of an individual to be tested. Methods for determining sample suitability and / or adequacy are provided.

[0098] In some embodiments, the subject may be referred to a specialist such as an oncologist, surgeon, or endocrinologist. The specialist may likewise obtain a biological sample for testing or refer the individual to a testing center or laboratory for submission of the biological sample. In some cases the medical professional may refer the subject to a testing center or laboratory for submission of the biological sample. In other cases, the subject may provide the sample. In some cases, a molecular profiling business may obtain the sample. VI. Administration of Therapeutic Compositions

[0099] The therapy provided herein may comprise administration of a combination of therapeutic agents, such as a first therapy and a second therapy. The therapies may be administered in any suitable manner known in the art. For example, the first and second treatment may be administered sequentially (at different times) or concurrently (at the same time). In some embodiments, the first and second treatments are administered in a separate composition. In some embodiments, the first and second treatments are in the same composition.

[0100] Embodiments of the disclosure relate to compositions and methods comprising therapeutic compositions. The different therapies may be administered in one composition or in more than one composition, such as 2 compositions, 3 compositions, or 4 compositions. Various combinations of the agents may be employed.

[0101] The therapeutic agents of the disclosure may be administered by the same route of administration or by different routes of administration. In some embodiments, the therapy is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally,138923491.1 - 36 -intraventricularly, or intranasally. In some embodiments, the antibiotic is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. The appropriate dosage may be determined based on the type of disease to be treated, severity and course of the disease, the clinical condition of the individual, the individual's clinical history and response to the treatment, and the discretion of the attending physician.

[0102] The treatments may include various “unit doses.” Unit dose is defined as containing a predetermined-quantity of the therapeutic composition. The quantity to be administered, and the particular route and formulation, is within the skill of determination of those in the clinical arts. A unit dose need not be administered as a single injection but may comprise continuous infusion over a set period of time. In some embodiments, a unit dose comprises a single administrable dose.

[0103] Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the patient, the route of administration, the intended goal of treatment (alleviation of symptoms versus cure) and the potency, stability and toxicity of the particular therapeutic substance or other therapies a subject may be undergoing. VII. Pharmaceutical Compositions

[0104] In certain aspects, the compositions or agents for use in the methods, such as therapeutic agents or biomarker modulators, are suitably contained in a pharmaceutically acceptable carrier. The carrier is non-toxic, biocompatible and is selected so as not to detrimentally affect the biological activity of the agent. The agents in some aspects of the disclosure may be formulated into preparations for local delivery (i.e. to a specific location of the body, such as skeletal muscle or other tissue) or systemic delivery, in solid, semi-solid, gel, liquid or gaseous forms such as tablets, capsules, powders, granules, ointments, solutions, depositories, inhalants and injections allowing for oral, parenteral or surgical administration. Certain aspects of the disclosure also contemplate local administration of the compositions by coating medical devices and the like.

[0105] Suitable carriers for parenteral delivery via injectable, infusion or irrigation and topical delivery include distilled water, physiological phosphate-buffered saline, normal or lactated Ringer's solutions, dextrose solution, Hank's solution, or propanediol. In addition,138923491.1 - 37 -sterile, fixed oils may be employed as a solvent or suspending medium. For this purpose any biocompatible oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. The carrier and agent may be compounded as a liquid, suspension, polymerizable or non-polymerizable gel, paste or salve.

[0106] The carrier may also comprise a delivery vehicle to sustain (i.e., extend, delay or regulate) the delivery of the agent(s) or to enhance the delivery, uptake, stability or pharmacokinetics of the therapeutic agent(s). Such a delivery vehicle may include, by way of non-limiting examples, microparticles, microspheres, nanospheres or nanoparticles composed of proteins, liposomes, carbohydrates, synthetic organic compounds, inorganic compounds, polymeric or copolymeric hydrogels and polymeric micelles.

[0107] In certain aspects, the actual dosage amount of a composition administered to a patient or subject can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.

[0108] Solutions of pharmaceutical compositions can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0109] In certain aspects, the pharmaceutical compositions are advantageously administered in the form of injectable compositions either as liquid solutions or suspensions; solid forms suitable or solution in, or suspension in, liquid prior to injection may also be prepared. These preparations also may be emulsified. A typical composition for such purpose comprises a pharmaceutically acceptable carrier. For instance, the composition may contain 10 mg or less, 25 mg, 50 mg or up to about 100 mg of human serum albumin per milliliter of phosphate buffered saline. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like.

[0110] Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate. Aqueous carriers include water, alcoholic / aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride,138923491.1 - 38 -Ringer's dextrose, etc. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial agents, antgifungal agents, anti-oxidants, chelating agents and inert gases. The pH and exact concentration of the various components the pharmaceutical composition are adjusted according to well-known parameters.

[0111] Additional formulations are suitable for oral administration. Oral formulations include such typical excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. The compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.

[0112] In further aspects, the pharmaceutical compositions may include classic pharmaceutical preparations. Administration of pharmaceutical compositions according to certain aspects may be via any common route so long as the target tissue is available via that route. This may include oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients. For treatment of conditions of the lungs, aerosol delivery can be used. Volume of the aerosol is between about 0.01 ml and 0.5 ml.

[0113] An effective amount of the pharmaceutical composition is determined based on the intended goal. The term “unit dose” or “dosage” refers to physically discrete units suitable for use in a subject, each unit containing a predetermined-quantity of the pharmaceutical composition calculated to produce the desired responses discussed above in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the protection or effect desired.

[0114] Precise amounts of the pharmaceutical composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting the dose include the physical and clinical state of the patient, the route of administration, the intended goal of treatment (e.g., alleviation of symptoms versus cure) and the potency, stability and toxicity of the particular therapeutic substance.138923491.1 - 39 -VIII. Kits

[0115] Certain aspects of the present invention also concern kits containing compositions of the invention or compositions to implement methods of the invention. In some embodiments, kits can be used to evaluate one or more biomarkers. In certain embodiments, a kit contains, contains at least or contains at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 100, 500, 1,000 or more probes, primers or primer sets, synthetic molecules, antibodies, or inhibitors, or any value or range and combination derivable therein. In some embodiments, there are kits for evaluating biomarker activity or level in a cell.

[0116] Kits may comprise components, which may be individually packaged or placed in a container, such as a tube, bottle, vial, syringe, or other suitable container means.

[0117] Individual components may also be provided in a kit in concentrated amounts; in some embodiments, a component is provided individually in the same concentration as it would be in a solution with other components. Concentrations of components may be provided as 1x, 2x, 5x, 10x, or 20x or more.

[0118] Kits for using probes, antibodies, synthetic nucleic acids, nonsynthetic nucleic acids, and / or inhibitors of the disclosure for prognostic or diagnostic applications are included as part of the disclosure. Specifically contemplated are any such molecules corresponding to any biomarker identified herein, which includes antibodies that bind to such biomarkers as well as nucleic acid primers / primer sets and probes that are identical to or complementary to all or part of a biomarker, which may include noncoding sequences of the biomarker, as well as coding sequences of the biomarker.

[0119] In certain aspects, negative and / or positive control nucleic acids, antibodies, probes, and inhibitors are included in some kit embodiments. In addition, a kit may include a sample that is a negative or positive control for methylation of one or more biomarkers.

[0120] It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein and that different embodiments may be combined. The claims originally filed are contemplated to cover claims that are multiply dependent on any filed claim or combination of filed claims.138923491.1 - 40 -IX. Examples

[0121] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention. Example 1: Novel plasma metabolites with mechanistic and clinical links in a neurovascular disease, cavernous angioma

[0122] Cerebral cavernous angiomas (CAs) affect 0.5% of the population, predisposing to serious neurologic sequelae from brain bleeding. A leaky gut epithelium associated with a permissive gut microbiome, was identified in patients who develop CAs, favoring lipid polysaccharide producing bacterial species. Micro-ribonucleic acids (miRNAs) along with plasma levels of proteins reflecting angiogenesis and inflammation were also previously correlated with CA and CA with symptomatic hemorrhage (CASH). Here we identify novel plasma metabolites (p<0.05, FDR corrected; Bayes>3), including cholic acid and hypoxanthine distinguishing CA patients, while arachidonic and linoleic acids distinguished those with SH. Plasma metabolites were linked to the permissive microbiome genes, and to previously implicated disease mechanisms. The metabolites distinguishing CA with SH were validated in an independent propensity matched cohort, and their integration, along with levels of circulating miRNAs, enhanced the performance of plasma protein biomarkers (up to 85% sensitivity and 80% specificity). Plasma metabolites reflect CAs and their hemorrhagic activity. A model of their multiomic integration is applicable to other pathologies. A. Introduction

[0123] Cavernous angiomas (CAs), also known as cerebral cavernous malformations, affect more than one million Americans (1). They are neurovascular lesions characterized by dysmorphic dilated capillaries, or caverns, lined by a leaky endothelium prone to hemorrhage (2). The only current treatments of CAs are surgical resection of symptomatic lesions, or radio- surgical ablation of lesions, which are associated with high morbidity as well as costs and are limited in cases of multiple brain lesions (2). Hence, there is a strong interest in developing non-surgical therapies based on mechanistic pathobiology (3-5).138923491.1 - 41 -

[0124] The clinical course of CA disease remains highly variable (2,6). Some patients live unfettered lives despite CA, while others could be severely disabled by the disease (2,6). While the risk of an initial cavernous angioma manifesting symptomatic hemorrhage (CASH) remains low, approximately 0.08% per year, a CASH is more than tenfold more likely to rebleed with cumulative disability as compared to lesions that never bled (2,6,7). Therefore, there is a need for accurate biomarkers to distinguish high risk cases, selecting them for invasive or novel interventions, and to track disease status, progression, and response to therapies (5,8).

[0125] Herein, the differential plasma metabolome was assessed for the first time in CA patients to investigate possible mechanistic links with the lesional transcriptome, as well as the differential gut microbiome and plasma proteome previously implicated in CA (24). The inventors hypothesize that (1) the plasma metabolome identifies novel molecules associated with the diagnosis of CA as well as its cardinal clinical manifestation of symptomatic hemorrhage (SH); (2) metabolites associated with clinical features are mechanistically related to genes implicated in CA disease and the permissive microbiome; and (3) we propose that multiomic integration of these metabolites with plasma protein and miRNA levels using Bayesian modeling, implemented using machine learning (ML) algorithms, may enhance previously proposed diagnostic associations with symptomatic hemorrhage, the critical clinical feature of this disease. B. Results 1. Plasma ratio levels of fifteen metabolites, including cholic acid and hypoxanthine, distinguished CA patients from healthy non-CA subjects

[0126] The unsupervised PLS-Discriminant analysis (PLS-DA) of the metabolome identified 15 molecules with differential plasma ratio levels (p<0.05, false discovery rate [FDR] corrected) in a discovery cohort comprised of 53 consecutive CA patients enrolled between April 2017 and August 2018 compared to 17 healthy non-CA controls (FIG. 1A, Supp. Table 1, Supp. Table 2). This discovery cohort contains the same patients reported in our recently published study on permissive microbiome in CA disease (12). In-silico integrative analyses with the microbiome bacterial species that had previously been shown in different abundance (p<0.01, FDR corrected) among CA vs healthy non-CA (i.e., 16S-RNA seq) revealed interactions of cholic acid and hypoxanthine with genes of Bifidobacterium adolescentis, Faecalibacterium prausnitzii, and Odoribacter splanchnicus (FIG. 2) (12). Of interest, ten genes linking the three species to hypoxanthine were identified within shotgun138923491.1 - 42 -metagenomic sequencing of the differential microbiome of the same CA versus non-CA subjects (12).

[0127] Further in-silico analyses showed that nine of the 15 differential metabolites were involved in 20 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways commonly enriched within the previously published transcriptome of human lesional neurovascular units (NVUs) (25) and differential proteome of CA disease (p<0.05, FDR corrected; Bayes factor>3; FIG.2, FIG.6). Of interest, cholic acid and hypoxanthine were related to PI3K-AKT, MAPK, NF-KB, and Rap1 signaling (FIG. 2) previously implicated the pathogenesis of CAs (11,15- 17,26,27).

[0128] The individual receiver operating characteristic (ROC) curves for each of the fifteen metabolites showed “poor” or “fair” sensitivity / specificity to distinguish CA and non-CA healthy subjects (Supp. Table 2). A three step Bayesian ML approach, however, further derived a weighted combination (Supplemental Results) of five differential plasma metabolites able to distinguish CA and non-CA healthy subjects of the discovery cohort with 87.5% sensitivity and 89% specificity: Diagnostic CA biomarker = 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4- cholestenoic acid] + 0.07

[0129] Canonical values estimated with this model were higher in CA patients compared to healthy non-CA patients (p<0.0001). This sensitivity and specificity of the combined metabolites in differentiating CA from non-CA subjects is similar to that reported with the permissive microbiome in the same subjects (12). Plasma metabolites reflecting the permissive microbiome and other mechanisms distinguishing CA from non-CA subjects are much more amenable to assays in individual subjects than analyses of fecal bacterial composition. 2. The plasma ratio levels of four metabolites, including linoleic and arachidonic acids, distinguished CASH and cavernous angioma without symptomatic hemorrhage (non-CASH) patients

[0130] The results of the unsupervised PLS-DA identified showed that the plasma ratio levels of linoleic and arachidonic acids were greater in CASH (n=5) compared to non-CASH (n=48) patients in the discovery cohort, and lower for 1-oleoyl-sn-glycero-3- phosphoethanolamine and glycodeoxycholic acid (all: p<0.05, FDR corrected; FIG.1B, Supp. Table 3A). Arachidonic acid in fact interacts with specific genes of Enterobacter cloacae,138923491.1 - 43 -which has been found to be differentially abundant in CASH compared to non-CASH patients (12). Further in-silico analyses showed that arachidonic, linoleic, and glycodeoxycholic acids were mapped through 23 common KEGG pathways across the CA transcriptome and proteome (FIG. 7), including PI3K-Akt, MAPK, HIF-1, and Rap1 signaling. Of interest, arachidonic acid was specifically correlated with 11 enriched-KEGG pathways common across the transcriptome, proteome, and metabolome datasets (p<0.05, FDR corrected; Bayes factor>3; FIG.3).

[0131] Metabolites also distinguished aggressive versus non-aggressive CA subjects, and familial versus sporadic cases (Supplemental Data; FIGS. 11-13), groups also previously manifesting differential microbiomes (12) and different plasma protein levels (28). The potential significance of these associations is presented in the Supplemental Data. 3. The four differentially present plasma metabolites identified in CASH patients, compared to non-CASH, were validated in an independent propensity matched cohort

[0132] A CASH is a cardinal event in the clinical course of CA disease9. An independent propensity matched cohort of CASH (n=20) and non-CASH (n=20) patients identified among subsequent prospectively enrolled subjects, was used to validate the metabolomic findings (Supp. Table 4). Twenty CASH and 20 non-CASH patients were propensity score matched. The supervised PLS-DA also showed that plasma ratio levels of linoleic (p=0.003) and arachidonic (p=0.06) acids were greater in CASH compared to non-CASH patients of the validation cohort, and lower for 1-oleoyl-sn-glycero-3-phosphoethanolamine (p=0.02) and glycodeoxycholic acid (p=0.0002) in CASH compared to non-CASH patients, as in the discovery cohort, and in the same direction (FIG.8; Supp. Table 3B). 4. Nineteen plasma miRNAs are differentially expressed in the propensity matched cohort of 20 CASH and 20 non-CASH patients

[0133] Differential expression analyses identified 19 DE plasma miRNAs (p<0.05, FDR corrected) between the CASH and non-CASH patients of the propensity matched cohort (Supp. Table 5). Among these 19 DE miRNAs, 8 were assessed using RT-qPCR. Plasma DE miR- 486-5p, miR-25-3p, miR-16-5p, miR-183-5p and miR-501-3p were independently discovered in previous preliminary analyses20. In addition, miR-182-5p, miR-20a-5p and miR-92a-3p had at least 2 putative gene targets within the transcriptome of lesional human CA NVUs, (20,25) related to enriched KEGG pathways with documented mechanistic role in the138923491.1 - 44 -physiopathogenesis of CAs including HIF-1, MAPK, PI3K-Akt, Rap1 and VEGF signaling (15-17,29). 5. Multi-omics integration of plasma levels of metabolites, miRNAs and proteins enhances the diagnostic association with CASH

[0134] Weighted combination of protein biomarkers had been shown to distinguish CASH versus non-CASH subjects, and several plasma miRNAs were differentially expressed in these subjects (20). We compared the levels of differentially identified metabolites to levels of 19 proteins previously implicated in CA disease (8,18,19) in the same subjects. Except for few interesting correlations (i.e., linoleic acid and C reactive protein, tauroursodeoxycholic acid and IL-10, glycodeoxycholic acid and vascular endothelial growth factor, and phenylalanylphenylalanine and ANG-1), levels of the vast majority of metabolites did not correlate with protein biomarker levels, hence contributing independent information (FIG.9).

[0135] Levels of DE miRNAs had also not been previously considered in combined biomarker analyses. We hence sought to examine whether the combination of previously identified proteins and miRNAs differentiating CASH from non-CASH along with the novel metabolites can enhance the sensitivity and specificity of the diagnostic association.

[0136] First, the previously published weighted combination of four proteins was again confirmed to distinguish CASH and non-CASH patients of the independent propensity score matched cohort with 60% sensitivity and 70% specificity (Accuracy=69.3%, area under the curve [AUC]= 69.2%), in the same range as reported previously in a different cohort. (20) A three steps Bayesian approach using a leave-one-out cross-validation (CV) ML framework was then implemented to determine if a weighted combination of plasma levels of metabolites, proteins and miRNAs improves the diagnostic association with CASH (FIG. 10). The integrative weighted combination of plasma levels of one metabolite, three miRNAs and the same protein CASH biomarkers improved the diagnostic association distinguishing CASH patients versus non-CASH patients to 80% sensitivity and 95% specificity (Accuracy=87.5%, AUC=90.3%, Akaike Information Criterion [AIC]= 45.6; FIG.4): Integrated diagnostic CASH biomarker = -3.37*[sCD14] +1.47*[CRP] -0.36*[VEGF]- 0.57*[IL-10] +316.54*[linoleic acid]r-6.06*[miR-20a-5p]r+ 5.41*[miR-25-3p]r+1.26*[miR- 486-5p]r

[0137] The canonical values estimated using this integrated diagnostic CASH biomarker were higher in CASH compared to non-CASH patients (p<0.0001; FIG.4).138923491.1 - 45 -

[0138] A parallel 10-fold cross validation ML approach yielded similar results with 85% sensitivity and 80% specificity (Accuracy=82.5%, AUC=90.8%, AIC=31.9). Refer to supplemental data for more results. C. Supplemental Results 1. Statistical analyses of the demographics of the discovery and independent propensity matched validation cohort

[0139] The comparisons of the demographics of the discovery and independent propensity score matched cohort were performed with independent samples t-test, Mann-Whitney U-test, χ2-test, or Fisher’s exact test using SPSS v22.0 (IBM, Armonk, NY, USA). Continuous variables were tested for normality using Shapiro-Wilk test. All p-values were considered statistically significant at α<0.05. 2. Correlation of plasma levels of proteins and differentially expressed metabolites

[0140] The correlation between the plasma protein levels and normalized metabolite values were assessed using Pearson's coefficient. A two-sided t test was used to estimate the p-value with FDR correction using the R software. The analyses showed that the plasma levels of 5 metabolites and protein were correlated (|r|>0.5; p<0.05, FDR corrected). These include correlations between (1) linoleic acid and C reactive protein (CRP), (2) tauroursodeoxycholic acid and IL-10, (3) glycodeoxycholic acid and vascular endothelial growth factor (VEGF), (4) glycocholic acid and VEGF, as well as (5) Phenylalanylphenylalanine and angiopoietin-1 (ANG-1). These results suggest that these molecules have mechanistic co-involvement. Thereafter, correlational feature selection was used to only include molecules with low inter- correlations and high predictive ability in the diagnostic weighted combinations (FIG.9). 3. Transcriptome enriched KEGG pathways

[0141] The transcriptome of human lesional NVUs of CA identified 1542 DEGs (p<0.05, FDR corrected). The enriched-KEGG pathway analyses were then performed independently on each of the two lists and found 35 enriched-KEGG pathways (p<0.05, FDR corrected; Bayes>3) for the upregulated DEGs, and 65 (p<0.05, FDR corrected; Bayes>3) for downregulated DEGs. 4. Transcriptome, metabolome, and proteome analyses in CA disease

[0142] The plasma levels of 15 metabolites were different between CA and healthy non-CA subjects (p<0.05, FDR corrected; Bayes factor>3) of the discovery cohort (FIG. 1A, Supp.138923491.1 - 46 -Table 2). Among these 15 metabolites, 9 had valid KEGG IDs identified using PubChem. Of these 9 metabolites, 7 (including 2 with microbiome links (FIG. 2, FIG. 6)) were shown to interact with or affect 337 KEGG pathways. Of the 337 pathways, 51 overlapped with the DEG enriched-KEGG pathways within the lesional transcriptome of CA disease. Of those 51 enriched-KEGG pathways, 20 also overlapped with enriched-KEGG pathways identified within the differential plasma proteome of CA disease, including 11 pathways with documented roles in CA pathogenesis, such as PI3K-Akt, HIF-1, MAPK, and Rap1 signaling (FIG.6).

[0143] Further analyses on the overlap between the KEGG pathways interacting with cholic acid and hypoxanthine and the enriched-KEGG pathways between the (1) transcriptome, (2) proteome identified a total of 17 common pathways, including 9 with mechanistic relevance to CA disease, including PI3K-AKT, MAPK, NF- ^B, and Rap1 signaling (FIG.6). 5. Transcriptome, metabolome, and proteome analyses in CASH versus non-CASH patients

[0144] PLS-Discriminant Analysis (PLS-DA) identified four metabolites differently expressed in the plasma of CASH vs. non-CASH patients included within the discovery cohort (FIG. 1B, Supp. Table 3A), of which arachidonic acid, linoleic acid, and glycodeoxycholic acid had valid compound IDs. Of these three metabolites, arachidonic acid had links to the microbiome (FIG.3). From these three metabolites, 341 KEGG pathways that interact with or are affected by these metabolites were identified. Of the 341 pathways, 57 overlapped with enriched-KEGG pathways identified within the human lesional transcriptome of CA. Those 57 enriched-KEGG pathways were further narrowed down to 23 that overlapped across differential metabolome, transcriptome and proteome, and included nine CA relevant pathways, such as PI3k-Akt, HIF-1, MAPK, and Ras signaling (FIG.7).

[0145] Further analyses on arachidonic acid showed a total of 23 common enriched-KEGG pathways that overlapped across metabolomic, transcriptomic and proteomic data, of which 11 were previously reported with a mechanistic link in CA disease (FIG.3). 6. The plasma of ratio levels of six metabolites, including bilirubin, distinguished aggressive vs. non-aggressive CA patients

[0146] Aggressivity of CA disease is an important determinant for understanding CA clinical course and developing therapeutic strategies. Among the 53 CA patients of the discovery cohort, 19 were classified into aggressive and 34 as non-aggressive disease based on138923491.1 - 47 -their clinical records. Aggressive CA disease was defined as: (1) age of symptom onset prior to 18 years of age, (2) a history of two or more CASH events, (3) greater than 25 susceptibility weighted imaging (SWI) lesions, or (4) greater than 5 T2-weighted lesions >4 mm in diameter. The differential metabolome between aggressive and non-aggressive disease CA-patients included in the discovery cohort identified 6 metabolites (p<0.05, FDR corrected; FIG. 11, Supp. Table 6) in the discovery cohort. Among these metabolites, bilirubin, as well as cis-9- hexadecenoic and tauroursodeoxycholic acids interacted with 19 CA-enriched KEGG pathways that also overlapped across the transcriptome and proteome of CA disease. Of these 19, the literature showed 10 to be KEGG pathways with prior established relevance to CA disease (FIG.12). 7. Three metabolites, including glycodeoxycholic acid and glycocholic acid, distinguished familial- vs. sporadic-CA patients

[0147] CA patients including within the discovery cohort harboring (1) multiple lesions throughout the brain on T2-weighted imaging or SWI, (2) a documented CCM1, CCM2, or CCM3 germline mutation, and / or (3) first-degree relative with a history of CA were classified as familial-CA (n=25). Patients showing a solitary or a cluster of lesions associated with a developmental venous anomaly lesion were identified as sporadic-CA patients (n=28). The plasma levels of glycodeoxycholic and glycocholic acids, as well as decanoyl-L-carnitine were different (p<0.05, FDR corrected; FIG. 11, Supp. Table 7) between familial- and sporadic- CA patients of the discovery cohort. Two hundred thirty-one pathways were associated with the genes that interact with or are affected by these 3 metabolites. Among these 231 pathways, 37 overlapped with the enriched-KEGG pathways identified in the human lesional NVUs transcriptome. Of the 37 enriched-KEGG pathways, 12 also overlap with the proteome. Seven of these pathways had CA relevance from the literature, including PI3K-Akt, HIF-1, and MAPK signaling (FIG.13). 8. Diagnosis of CA disease and its characteristics with metabolites alone

[0148] Weighted combination to distinguish CA patients and healthy non-CA subjects. The best weighted combination of differential plasma metabolites identified between CA and healthy non-CA was able to distinguish CA patients and non-CA healthy of the discovery cohort with 87.5% sensitivity and 89% specificity: L(CA) = 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4-cholestenoic acid] + 0.07138923491.1 - 48 -

[0149] Canonical values estimated with this model were higher in CA patients compared to healthy non-CA patients (p<0.0001).

[0150] Weighted combination to distinguish aggressive and non-aggressive CA patients. The weighted model to distinguish patients with aggressive and non-aggressive disease of the discovery cohort achieved 85% sensitivity and 79% specificity: L(non-aggressive disease) = 3682.02 * [cis-9-hexadecenoic acid] – 19165.94 * [1-palmitoyl- sn-glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.48

[0151] The canonical values derived from this model were lower in CA patients with aggressive disease (p<0.0001).

[0152] Weighted combination to distinguish familial- and sporadic- CA patients. Finally, the best weighted model, including only the plasma metabolites differentially expressed between the familial-CA and sporadic-CA patients of the discovery cohort, achieved 37% sensitivity and 86% specificity. L(Familial-CA) = 1236.91 * [decanoyl-L-carnitine] – 0.37

[0153] The canonical values derived from this last analysis trended higher in familial-CA disease compared to sporadic-CA disease (p=0.09). D. Discussion

[0154] We performed unsupervised differential plasma metabolomic analysis in CA patients versus healthy non-CA subjects, and in CA patients with different disease features. Multiomic integrative analyses showed that several differential metabolites were associated not only with enriched-KEGG pathways dysregulated within the transcriptome of lesional NVUs and plasma proteome, but also with gut microbiota species showing differential relative abundances in CA patients. This is the first plasma metabolomic analysis in any neurovascular disease. Metabolites with different levels in CAs with and without SH, the most important clinical feature of the disease, were validated in a propensity matched independent patient cohort. A novel Bayesian approach implemented with ML algorithms showed that normalized levels of plasma metabolites and miRNAs enhanced the performance of a previously published protein-based CASH biomarker. This integrative biomarker development strategy is applicable in other pathologies.

[0155] The initial differential analyses of the metabolome showed that the plasma concentrations of cholic, glycocholic, glycodeoxycholic, and tauroursodeoxycholic acids were138923491.1 - 49 -different between CA patients and healthy non-CA subjects. Of interest, the plasma levels of glycocholic acid and VEGF were correlated (FIG.9).

[0156] The plasma levels of the vast majority of metabolites and putative proteins previously associated with CA disease did not correlate, and hence contributed complementary biomarker information (FIG. 9). Consistent with this observation, the three step Bayesian approach using a ML framework showed that multiomic integration improves the efficacy of CASH diagnosis, the most relevant clinical context in this disease. The molecules embedded in the best weighted biomarker combination have strong mechanistic rationale in CA disease.

[0157] We identify interactions of the differential plasma metabolome and proteome, lesion transcriptome, and gut microbiome associated with CA, resulting in cross-validation of postulated mechanisms of disease. Bayesian and ML algorithms implemented herein led to the development of highly accurate markers of CA diagnosis and CASH. The levels of mechanistically linked metabolites, miRNAs and proteins were validated in independent cohorts, and their weighted combination enhanced biomarker performance in relation to SH, the most relevant clinical context of use. The testing of these biomarkers in larger populations across multiple sites could lead to further confidence in new smart blood tests based on multi- omic mechanistic links in this and other diseases.138923491.1 - 50 -E. Tables Supplemental Table 1. Demographic characteristics and lesion features of human subjects in the discovery cohort Patients with Cavernous Angioma S A 9 F L C P EOthers 0 (0%) 4 (8.3%) 1 (5.9%)138923491.1 - 51 -Supplemental Table 2. The plasma levels of fifteen metabolites were different between cavernous angioma (CA) and healthy non-CA subjects (p<0.05, FDR corrected) Healthy P c n 1 O g p L 1 h g p mCc H a E n G a G li DaH icHLP e T yUrobilin 5280819 0.22±1.13 2.58±8.28.Supplemental Table 3. Four metabolites were differentially present in the plasma of (A) discovery cohort (p<0.05, FDR corrected), (B) independent propensity matched validation cohort (p<0.1, FDR corrected) of cavernous angioma with symptomatic hemorrhage (CASH) vs. cavernous angioma without symptomatic hemorrhage (non- CASH) patients138923491.1 - 52 -A PubChCASH Non-CASH Pem-4) L 1 p A ( GB CASH Non-CASH ± L 1 p A ( GSupplemental Table 4. Demographic characteristics of the propensity matched validation cohort including 20 cavernous angioma with symptomatic hemorrhage (CASH) and 20 cavernous angioma without symptomatic hemorrhage (non-CASH) patients S A G Ph BrNo 15 (75.0) 15 (75.0)138923491.1 - 53 -Supplemental Table 5. Nineteen plasma miRNAs were differentially expressed between CASH and cavernous angioma without symptomatic hemorrhage (non-CASH) patients included in the propensity matched scored Log2(Fold Adjusted p-value m m m m m m m m m m m m m m m m m m m138923491.1 - 54 -Supplemental Table 6. Six metabolites had different plasma levels in aggressive compared to non-aggressive cavernous angioma patients (p<0.05, FDR corrected) Aggressive Non-AggressivePlan 1 1 p 7 ( a B c TSupplemental Table 7. Three metabolites were differentially present in the plasma of familial- compared to sporadic- cavernous angioma (CA) patients (p<0.05, FDR corrected) P n n D G G138923491.1 - 55 -no nT8ms1ulel di)ni 33.8.6 8R CocicBAm( - - - -51 - - -1.1271.8 -65n-oitaziendoo ) ) ) )Im+(+(+(+()-()-)(+()-)(+()-()-()-(lyrnehd oEic ciPtg o cs ilodi*pae i ol yh c1D:0ldI 8:16 yc i n m1 nialc ihlaanLdcyalox cihAtn-pyaiclaoeoFC nilEale cci aat xEevdhcMPo ib Poyn niy enxolxooe opb-rdPi dotca 2iloocodcMsor s e a e n y L y i s t :yl iylHyL UyLhPlaDiL H D HcayLup81hC GcaG dnuo 1p.1m94o32C# 1 2 4 5 6 7 8 901112131 983136.0-842.613 684 8 - -85 094 984 234 7888 9291246 94 0 70 4 52 3 24 2 1. . .3 3 36 0 5. . .1 8 86 2 13 4 - - 5948434216583 1254925. . .66 -.63 4 6.3.4.5.45.4 - - - - - -75-)+)+)-)-)-)+)+)+)( ( ( ( ( ( ( (+(o dhc- icioa7-o4tdcy ne -o ic el-1axo ce 0 xabaL-l:8ci ey n d da:06:8o-3 cionuoenn1o odsrxeni1 1-eyne saaitEP ih udiH- b CPEPvixots wcienros c orca9durio otardelDacy ar uLAaTc -is i lliccaisBysLytLuy oep Hhc noidenalodheicfi1.1o rie 944tv3215161718191021222E*eb 9831F. Methods 1. CA patients and clinical parameters

[0158] For this prospective study, a discovery cohort of 53 consecutive CA patients (25 familial-CA, and 28 sporadic-CA) was enrolled at a single referral center (found on the world wide web at uchicagomedicine.org / ccm) between April 2017 and August 2018, during routine consultations or follow-up visits (Supp. Table 1). The diagnosis of CA disease was established using clinical 3-Tesla MRI scanners by a senior neurosurgeon (IAA) with more than 30 years of experience in CA disease management. Patients with partial or complete resection of CA or any prior brain irradiation were excluded (18,19,42).

[0159] In the discovery cohort, five patients experienced a CASH within the year preceding collection of the blood sample. A CASH is a cardinal event in the clinical course of CA disease, (9) and was defined as an overt hemorrhagic event, noted on diagnostic imaging, in conjunction with attributable neurological symptoms (43). An independent cohort was later recruited to validate the metabolomic findings. One hundred and nine consecutive CA subjects, enrolled between August 2016 and October 2020 included 20 CASH cases. These were best matched with 20 of the non-CASH cases for (1) age at enrollment, (2) gender (male / female), (3) phenotype (sporadic / familial), and (4) harboring brainstem lesion (yes / no). A one-to-one mapping with the single nearest neighbor was performed to match CASH and non-CASH pairs using STATA version 16.0 (College Station, TX, USA). The 20 CASH and 20 non-CASH patients who were most closely matched were included as the validation cohort.

[0160] Finally, 17 healthy non-CA subjects were also concurrently enrolled. Subjects were included if they did not have (a) any medical or neurologic condition requiring ongoing follow- up or medical treatment in the preceding year, (b) a history of concussion or brain trauma in the preceding year, (c) a history of prior brain irradiation at any time, (d) been pregnant or lactating in the preceding year, (e) used recreational, psychoactive, or neuroleptic drugs in the prior year.

[0161] All subjects gave written informed consent in compliance with the Declaration of Helsinki, and the study was approved by the University of Chicago Institutional Review Board, which is guided by ethical principles consistent with the Belmont Report, and comply with the rules and regulations of the US Department of Health and Human Services Federal Policy for the Protection of Human Subjects (56 FR 28003).138923491.1 - 58 -2. Whole blood collection and processing

[0162] Standard clinical 10mL heparinized vacutainer tubes (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA) were used to draw blood samples in conjunction with clinic visits. The plasma was isolated by centrifugation at 2300 rpm (1019 g) at 4 ^C for 10 minutes (AllegraX-30R, Beckman Coulter, Brea, California, USA). Subsequently 300μL of supernatant plasma was aliquoted into 1.7mL microcentrifuge tubes for storage at -80 ^C. These aliquots were used to assess the plasma metabolome, as well as predefined proteins and miRNAs. 3. Liquid chromatography-tandem mass spectrometry data acquisition and analyses for plasma metabolites in the discovery cohort

[0163] For each sample, 30 ^L of plasma was thawed and mixed with 120 ^L of 100% methanol spiked with 1.25 ^M sulfamethazine. As part of liquid chromatography-tandem mass spectrometry data acquisition (LC-MS / MS), the samples were resuspended in 120 ^L of a 1:1 water to methanol mixture. The samples were then spiked with 1 ^M of sulfadimethoxine, and transferred into a 96-wells autosampler plate. The plasma metabolome analysis was performed using an ultra-high performance Thermo Dionex Ultimate 3000 UHPLC (ThermoFisher, Waltham, MA, USA) coupled to an ultra-high resolution quadrapole time of flight Bruker Daltonics MaXis HD (Billerica, MA, USA) mass spectrometer. The data acquisition was performed using electrospray ionization in positive mode.

[0164] Data analyses were performed using a complete a lock mass correction using hexakis (1H, 1H, 2H-difluoroethoxy) phosphazene (Synquest Laboratories, Alachua, FL, USA) implemented within the Bruker Data Analysis Software. Feature detection was done with MZmine v2.38 software (found online at mzmine.github.io / changelog.html) (44). The MS2 file and quantification table were used in the Global Natural Products Social Molecular Networking feature based molecular networking workflow (45,46) to get both networks and annotations for the metabolites. Discovery cohort metabolomic quantifications were performed at the Center for Microbiome Innovation at the University of California San Diego. 4. Differential analyses of the plasma metabolome

[0165] The unsupervised differential metabolome was assessed with PLS-Discriminant Analysis (PLS-DA) using the R Software (47). PLS-DA was utilized to determine linear combinations of candidate molecules for biomarker development, rather than a Student t-test, which would show distinguishing power of an individual molecule. A random permutations138923491.1 - 59 -analysis on the peak values of the differentially expressed metabolite was performed to estimate the significance of the computed PLS-DA coefficients. Only the peaks with significant PLS- DA coefficients (p<0.05, FDR corrected) were selected. Normalized plasma concentrations of each metabolite were calculated for each patient. Unannotated peaks and peaks representing drug-related compounds were discarded. The supervised analyses to validate the metabolites of interest between CASH and non-CASH patients in the independent propensity-matched cohort followed the same approach. 5. Independent propensity-matched validation cohort

[0166] The fragmentation pattern of the differential plasma metabolites identified between patients with a CASH event in the prior year and non-CASH patients was validated in an independent propensity matched validation cohort using a supervised LC-MS / MS approach.

[0167] Metabolites were extracted using a 1:8 dilution (i.e., one volume of plasma for eight volumes of extraction solvent composed of 100% methanol spiked with internal standards).

[0168] The bile acids were assessed using 5µL of extracted supernatant injected onto an XBridge BEH C18 Column (Waters Corporation, Milford, MA, USA) fitted with an XBridge BEH C18 guard (Waters Corporation) at 45oC. The fatty acids and the others metabolites of interest were assessed using 5µL of the extracted supernatant injected onto an Acquity UPLC HSS T3 Column (Waters Corporation) fitted with an Acquity UPLC HSS T3 guard (Waters Corporation) at 45oC.

[0169] All metabolites were separated and analyzed by ultra high-pressure liquid chromatography quadrupole time-of-flight (UHPLC-QTOF) using the 1290 infinity II liquid chromatography system (Agilent, Santa Clara, CA, USA) coupled to the 6546 QTOF mass spectrometer (Agilent). The detection window was set at 100-1700 m / z with continuous infusion of the ESI TOF Biopolymer Analysis Reference Mix (Agilent) used for mass calibration for the assessments of bile and fatty acids as well as the other metabolites of interest.

[0170] All putative compound annotations from the discovery cohort were validated against authentic standards (MilliporeSigma, Darmstadt, Germany; Avanti Lipids, Alabaster, USA; Steraloids, Newport, USA) in the independent propensity matched validation cohort. Authentic standards and samples were run on the same instrument and their retention times, detected m / z, and fragmentation pattern were validated for all compounds (Supp. Table 8).

[0171] The data analyses were performed using MassHunter Profinder Analysis version B.10 software (Agilent) and confirmed by comparison with authentic standards. The138923491.1 - 60 -metabolomic quantifications were performed at Host-Microbe Metabolomics Facility at the University of Chicago. 6. Plasma protein assays

[0172] Plasma protein concentrations were determined using individual (ng / ml) enzyme- linked immunosorbent assay (ELISA) assays or multiplex (pg / ml) electrochemiluminescence immunoassays in accordance with manufacturer protocols (18-20).

[0173] Individual ELISA assays were performed using commercially available immunoassay kits to assess interleukin-10 (IL-10), CRP, and sCD14 (R&D Systems, Minneapolis, Minnesota, USA).

[0174] All plates were washed with a BioTek 405TS plate washer (BioTek Instruments, Winooski, VT, USA), and absorbances were measured using a Bio-Rad iMark plate reader (Bio-Rad, Hercules, CA, USA). The assays were performed in the Neurovascular Research team laboratory at the University of Chicago.

[0175] Multiplex electrochemiluminescence immunoassays plates (Meso Scale Diagnostics, Rockville, MD, USA) were used to quantify VEGF. Multiplex electrochemiluminescence immunoassays were processed using a V-plex multi-spot assay (Meso Scale Diagnostics). Plate was washed with a BioTek 405TS plate washer (BioTek Instruments, Winooski, VT, USA), and plasma levels measurements were assessed using Bio- Rad MESO QuickPlex SQ 120 (Meso Scale Diagnostics), by measuring light signal when the electrochemiluminescent labels are stimulated by electricity (12). The assessment was performed at the Flow Cytometry Core Facility at the University of Chicago.

[0176] In each plate, the plasma samples were loaded in parallel duplicate wells, and then averaged, as in ongoing protein biomarker development projects in our laboratory (8). Plasma values greater ±2 standard deviations from the mean for each group were excluded as statistical outliers. 7. Integrative analyses of differential metabolome, proteome, and transcriptome of human CA disease

[0177] The interacting genes associated with the differential metabolites identified in the metabolome of CA patients (p<0.05, FDR corrected) were queried using the Comparative Toxicogenomics Database (found online at ctdbase.org / ). The enriched-KEGG pathways containing at least one of the interacting genes associated with the differential metabolite were then identified using KEGG mapper (p<0.05, FDR corrected; Bayes>3) (FIG.5).138923491.1 - 61 -

[0178] The enriched-KEGG pathways (p<0.05, FDR corrected; Bayes Factor>3) associated with the upregulated and downregulated DEGs (p<0.05, FDR corrected) within the human lesional transcriptome of NVUs (Gene Expression Omnibus #GSE123968) (25) microdissected from CA lesions were queried independently using Lynx (found online at lynx.ci.uchicago.edu) (48). The common enriched-KEGG pathways between the differential metabolome and the lesional transcriptome were then identified (p<0.05, FDR corrected; Bayes>3) using KEGG mapper (found online at genome.jp / kegg / tool / map_pathway1.html) (FIG.5).

[0179] For the proteome, the coding genes of the plasma proteins with a documented role in CA disease were first queried using Uniprot (found online at uniprot.org / ) and Genecards (found online at genecards.org / ). KEGG pathway enrichment analysis was then performed using Lynx. Finally, the common enriched-KEGG pathways between the differential plasma proteome and metabolome were identified using KEGG mapper (p<0.05, FDR corrected; Bayes>3).

[0180] The common enriched-KEGG pathways between the differential plasma metabolome and proteome as well as transcriptome were finally integrated to create a cross- referenced master pathway list. 8. Integration of differential metabolome and microbiome of human CA disease

[0181] The genomes of the bacterial gut species showing different relative abundances in CA disease were queried using KEGG mapper (p<0.05, FDR corrected; Bayes>3) (12). The genes identified were further mapped into KEGG ortholog genes using AMON software (49) to extract reactions involving the ortholog genes and metabolites of interest. Shotgun sequencing was also queried to further support evidence for the presence of a reaction link (AMON) (FIG.5). 9. Three step Bayesian approach to assess the performance of the multi- omics diagnostic CASH biomarker

[0182] A three step Bayesian approach was implemented using a leave-one-out cross- validation ML framework to assess if a multi-omic integrative combination of plasma ratio levels of metabolites and miRNAs enhance the performance of the previously identified protein-based CASH biomarker (20). This three-step approach was first applied using the plasma ratio levels of (1) metabolites (all: p<0.05), (2) miRNAs, both validated in the138923491.1 - 62 -independent propensity scored matched validation cohort, and finally (3) the protein-based CASH biomarker as well as the metabolites and miRNAs.

[0183] Given the importance of clinical applicability, a smaller number of compounds with high sensitivity was preferred. The accuracy, specificity, sensitivity, receiver operating characteristic curve, and canonical values were computed for each model. The best performing models were selected by having the highest combination of sensitivity and specificity following the Youden index method (50-52). A parallel automatic ML framework of correlation-based feature selection (CFS), logistic linear regression with 10-fold cross validation, and tree-based model selection of the model with the lowest AIC value was used to support these results (53). Leave-one-out or 10-fold cross validation ML approaches reduce overfitting effects, while identifying molecules which would individually contribute to the model’s diagnostic association. In addition, AIC criteria allowed for selection of the least complex model to additionally also prevent overfitting (53). 10. Liquid chromatography-tandem mass spectrometry data acquisition and analyses for plasma metabolites

[0184] Discovery cohort. For each sample, 30 ^L of plasma was thawed and mixed with 120 ^L of 100% methanol spiked with 1.25 ^M sulfamethazine. The solution was homogenized for 5 minutes at 25 Hz using a Tissuelyser II (Qiagen, Hilden, Germany), and then stored at - 20°C for 2 hours. Afterwards, samples were centrifuged at 14000 rpm for 15 minutes, and 120 ^L of the supernatant was extracted and loaded in duplicate wells of a 96-wells plate. The plate was then concentrated using a CentriVap Benchtop Vacuum Concentrator (Labconco, Kansas City, USA) until dry, and stored at -80°C until further analysis.

[0185] As part of liquid chromatography-tandem mass spectrometry data acquisition (LC- MS / MS), the samples were resuspended in 120 ^L of a 1:1 water to methanol mixture. The samples were then spiked with 1 ^M of sulfadimethoxine, and transferred into a 96-wells autosampler plate. The plasma metabolome analysis was performed using an ultra-high performance Thermo Dionex Ultimate 3000 UHPLC (ThermoFisher, Waltham, MA, USA) coupled to an ultra-high resolution quadrapole time of flight Bruker Daltonics MaXis HD (Billerica, MA, USA) mass spectrometer. Chromatographic separation was performed using a Phenomenex Kinetex column (Torrance, CA, USA). Two solvents were used: solvent A consisted of LC-MS grade water with 0.1% formic acid while the mobile phase (i.e., solvent B) consisted of LC-MS grade acetonitrile with 0.1% formic acid. For each sample, 5μL of138923491.1 - 63 -solution was injected into a flow rate of 0.5 mL / min using the following parameters for the gradient (1) 0-1 min at 5% of solvent B, (2) 1-11 min linear increase to 100% B, (3) 11-11.5 min at 100% B, and (4) 11.5-12 min linear gradient to 5% of solvent B. The data acquisition was performed using electrospray ionization in positive mode.

[0186] Data analyses were performed using a complete a lock mass correction using hexakis (1H, 1H, 2H-difluoroethoxy) phosphazene (Synquest Laboratories, Alachua, FL, USA) implemented within the Bruker Data Analysis Software. Feature detection was done with MZmine v2.38 software. The parameters used were Centroid, Noise Level MS1 - 5.0E2 and MS2 - 5.0E1 (Mass Detection); MS Level 1, Minimum Time Span – 0.02, Minimum Height – 1.5E3, m / z tolerance – 0.02 m / z or 20 ppm (Chromatogram Builder); Algorithm – Local Min Search, Chromatographic Threshold – 0.01%, Search minimum in RT range – 0.3 min, Minimum relative height – 0.01%, Minimum absolute height – 1.5E3, Min ratio of peak top / edge – 2, Peak duration range – 0.02-0.50 min, m / z center calculation – Median, m / z range for MS2 scan pairing (Da) – 0.01, RT range for MS2 scan pairing (min) – 0.1; Isotopic Peak Grouper: m / z tolerance – 0.02 m / z or 20 ppm, Retention time tolerance – 0.3 min, Maximum charge – 4, Representative isotope – Most Intense (Chromatogram Deconvolution);m / z tolerance – 0.02 m / z or 20 ppm, Weight for m / z – 75, Retention time tolerance – 0.3 min, Weight for RT – 25; Gapfilling (peak finder): Intensity tolerance – 20 %, m / z tolerance – 0.005 m / z or 10 ppm, Retention time tolerance – 0.2; Peak Filter: area – 1.0E4 to 1.0E20 (Join Aligner). The MS2 file and quantification table were used in the Global Natural Products Social Molecular Networking feature based molecular networking workflow to get both networks and annotations for the metabolites. Discovery cohort metabolomic quantifications were performed at the Center for Microbiome Innovation at the University of California San Diego.

[0187] Independent propensity-matched validation cohort. The fragmentation pattern of the differential plasma metabolites identified between cavernous angioma with symptomatic hemorrhage (CASH) and cavernous angioma without symptomatic hemorrhage (non-CASH) patients was further validated in an independent propensity matched validation cohort using a supervised LC-MS / MS approach. Metabolites from plasma samples were extracted using a 1:8 dilution (i.e., 1 volume of plasma for 8 volumes of extraction solvent composed of 100% methanol spiked with internal standards). Plasma samples were extracted at -80oC for 1 hour. Samples were centrifuged at 20,000xG for 15 min at -10oC. Two-hundred µL of the supernatant was dried down under nitrogen stream at 1 L / min (bottom)-30 L / min (top) at 30oC using the SPE Dry 96 Dual (Biotage, Uppsala, Sweden). The samples were then resuspended in 200µL138923491.1 - 64 -of 1:1 water:methanol diluent, and mixed at 1000 rpm for 15 min at 4oC using a thermomixer (Eppendorf). Samples were then centrifuged at 20,000G for 15 min at 4oC to remove insoluble debris, and 150µL of extracted supernatant was taken through subsequent analysis on an Agilent 1290 infinity II liquid chromatography system coupled to an Agilent 6546 QTOF mass spectrometer, equipped with an Agilent Jet Stream Electrospray Ionization source. The detection window was set to 100-1700 m / z with continuous infusion of a reference mass (Agilent ESI TOF Biopolymer Analysis Reference Mix) for mass calibration.

[0188] Bile acids. Bile acids were analyzed in negative mode and 5µL of extracted supernatant was injected onto an XBridge BEH C18 Column (Waters Corporation, Milford, MA, USA) fitted with an XBridge BEH C18 guard (Waters Corporation) at 45oC. The mobile phase A was water with 0.1% formic acid, while the mobile phase B was acetone with 0.1% formic acid. Gradient elution started with 28% of the mobile phase B with a flow rate of 0.4 mL / min for 1 min, and linearly increased to 33% over 5 min, then to 65% over 14 min. The flow rate was then increased to 0.6 mL / min, while the mobile phase B was increased to 98% over 0.5 min. These conditions were held constant for 3.5 min. Then, re-equilibration was performed for 3 min at a flow rate of 0.4 mL / min with 28% of the mobile phase B. The electrospray ionization conditions were set with the capillary voltage at 3.5 kilovolts (kVs), nozzle voltage at 2 kVsA ten-point calibration curve of glycodeoxycholic acid was generated, starting at a concentration of 100µg / mL diluted in 1:1 water:methanol followed by nine 1:3 serial dilutions.

[0189] Fatty acids and others metabolites. The fatty acids and other metabolites of interest were assessed using 5µL of the extracted supernatant injected onto an Acquity UPLC HSS T3 Column (Waters Corporation) fitted with an Acquity UPLC HSS T3 guard (Waters Corporation) at 45oC. The mobile phase A was water with 0.1% formic acid and mobile phase B was 98% acetonitrile with 0.1% formic acid. Gradient elution started with 5% of the mobile phase B with a flow rate of 0.5 mL / min for 1 min, and linearly increased to 75% over 1 min, then to 100% over 8 min. Column washing was performed at 100% of the mobile phase B for 4 min. Re-equilibration was performed for 3 min with 5% of the mobile phase B. Fatty acids and bile acids were analyzed in negative mode with capillary voltage at 3.5kVs and nozzle voltage at 2kVs while other metabolites were analyzed in positive mode with nozzle voltage at 500Vs. An additional Level 1 confirmation was completed to support the identification of linoleic acid using known standards of linoleic and rumenic acids (FIG.14).138923491.1 - 65 -

[0190] Data analysis was performed using MassHunter Profinder Analysis software (version B.10, Agilent Technologies) and confirmed by comparison with authentic standards. For quantification of metabolites, normalized peak areas were calculated by dividing raw peak areas of targeted analytes by raw peak areas of analogous internal standards.

[0191] The metabolomic quantifications were performed at Host-Microbe Metabolomics Facility at the University of Chicago. 11. Gut Microbiome Analyses

[0192] Gut microbiome analyses on a larger cohort of CA patients and healthy non-CA subjects was previously published by our group. That report included gut microbiome data on the same patients enrolled herein in metabolome and plasma protein assays. The report also includes detailed methods of stool collection, 16S rRNA gene sequencing, metagenomics shotgun sequencing and analyses of bacterial abundance.

[0193] The 16S-sequencing libraries (Project ID= PRJEB35505) are available at the European Molecular Biology Laboratory- European Nucleotide Archive EMBL-ENA (found online at ebi.ac.uk / ena / data / view / PRJEB35505).

[0194] The metagenomic shotgun sequencing libraries (BioProject ID= PRJNA629755) are available at the Sequence Read Archive at National Center for Biotechnology Information (found online at ncbi.nlm.nih.gov / bioproject / PRJNA629755). 12. Differential microbiome analyses and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways

[0195] Following 16S analyses of the differentially detected bacterial species, the corresponding genomes, ortholog genes, and pathways in CA and the disease sub-categories were extracted from the KEGG database using the REST API (found online at kegg.jp / kegg / rest / keggapi.html). The python library KEGG-parser (version 0.0.1) was used to parse the queried data into a dictionary format. The annotation of metabolite origins via networks AMON library implemented in python (Python Software Foundation, Fredericksburg, VA, USA) was used to perform batch query and find reactions that involved genes differentially detected in the 16S experiment and metabolites detected in the metabolome experiment.

[0196] Microbiome shotgun sequencing resulted as an abundance matrix between the UniRef90 proteins within each detected microbiome species and CA patient samples. The Uniprot protein IDs were mapped through the KEGG REST API into the KEGG ortholog138923491.1 - 66 -genes. The AMON python library was used for the batch query and verifying the reactions involving detected genes in the shotgun sequencing experiment and metabolites detected in the metabolome experiment. 13. Transcriptome and enriched-KEGG pathways analyses

[0197] The transcriptome of human lesional CA neurovascular units (NVUs) of surgically resected CA from 5 patients and autopsy samples from 3 healthy non-CA subjects has previously been published by our team. NVUs were dissected using laser capture microdissection. Following, RNA isolation and sequencing were completed to determine genes differentially expressed in CA lesions compared to the NVU of healthy autopsy tissue. RNA was then extracted using an RNA isolation kit (RNeasy Micro Kit, Qiagen). cDNA libraries were generated using commercial low-input strand-specific RNA-Seq kits (Clontech) and sequenced on the Illumina HiSeq 4000 platform using single-end 50-bp reads (Illumina). The raw sequencing data (accession number= GSE123968) are available in the National Center for Biotechnology Information’s Gene Expression Omnibus database.

[0198] Differentially expressed gene (DEG) analyses were conducted using DESeq2, with an additive model for batch effect correction when necessary. DEGs were then classified into (1) upregulated, and (2) downregulated genes in CA patients (|Fold Change|>1.5; p<0.05, false discovery rate [FDR] corrected). Using these two gene lists, enrichment analysis was generated with the web-based bioinformatic tool Lynx (found online at lynx.ci.uchicago.edu) to extract two sets of over-represented KEGG pathways (p<0.05, FDR corrected). 14. Correlation between plasma protein levels and differentially expressed metabolites

[0199] The Pearson’s correlation was assessed based on the normalized metabolite measurement x and plasma protein concentration y from matched patients with both metabolome and plasma proteome data. The test statistic was based on Pearson's coefficient cor(x, y) and followed a t distribution with length(x)-2 degrees of freedom, assuming the samples followed independent normal distributions. A two-sided test was used to estimate the p-value. The p-values were corrected for multiple tests from all the metabolite-plasma protein pairs using the FDR B&H method. All the above steps were completed using the R statistics library.138923491.1 - 67 -15. Plasma miRNome sequencing and differential expression analyses

[0200] Total RNAs from 100 ^l of plasma was extracted using the miRNeasy Serum / Plasma Kit (Qiagen, Hilden, Germany) following the manufacturer recommendation. cDNA libraries were then generated with commercially available Illumina small RNA-Seq kits (Clontech, Mountain View, CA, USA) and sequenced with the Illumina HiSeq 4000 platform (Illumina, San Diego, CA, USA) using single-end 50-bp reads, at the University of Chicago Genomics Core.

[0201] The differential expression analyses were conducted using R bioconductor package DESeq2, and considered significant at p<0.05, FDR corrected. The in-silico putative gene targets analysis of the differentially expressed (DE) microRNAs (miRNAs) was performed using miRWalk 3.0. Gene targets were identified for the 3 different gene locations (3′ untranslated region [UTR], 5′ UTR, and coding sequence) using a random forest tree algorithm with a bonding prediction probability higher than 95%. Only putative gene targets that appeared in at least 2 of the 3 databases were considered, and they were then queried within the transcriptome of human lesional CA NVUs.

[0202] The DE plasma miRNAs were selected to be assessed using reverse transcription quantitative PCR (RT-qPCR) if they (1) were previously identified in preliminary analyses, and / or (2) had putative gene targets within the transcriptome of human lesional CA related to at least 1 dysregulated KEGG pathway related to CA disease. 16. RT-qPCR proof of feasibility

[0203] Relative and absolute quantifications of a panel of 6 pre-selected DE miRNAs were assessed using RT-qPCR. An exogenous spike-in control, miR-cel-39-3p, was added to all plasma samples prior to extraction and then measured to correct for extraction efficiency. The absolute quantification (i.e., number of miRNAs strands / ^l) of each miRNA was estimated using a standard curve comprised of serial dilutions of known concentrations of the miRNAs of interest.

[0204] For the relative quantification, miR-423-5p was used as an endogenous control as it is expected to be expressed at equal levels across tissue types and samples. This was validated using the NormFinder software, as miR-423-5p was shown to have the most stable expression across the controls tested (found online at moma.dk / normfinder-software). For each miRNA, a relative quantification value greater than ±3 standard deviations away from the mean was138923491.1 - 68 -defined as an outlier. Statistical analysis was performed on Prism (GraphPad, San Diego, California) using a Mann-Whitney test. 17. Assessment of selected DE plasma miRNAs using RT-qPCR

[0205] The total RNA was first extracted from plasma using the MagMAX mirVana Total RNA Isolation Kit (Thermo Fisher, Waltman, MA, USA). In addition, an exogenous control C. elegans miR-39-3p (1.5x1010copies of cel-miR-39-3p in 5µl) was spiked in during the total RNA extraction in order to assess the extraction efficiency, as well as to ensure the inter-plate reproducibility of the RT-qPCR. RT-qPCR was performed using the TaqMan Advanced miRNA Assays Kit (Thermo Fisher). A miR-Amp reaction was performed to amplify miRNAs prior to RT-qPCR using the QuantStudio3 (Thermo Fisher). The Cq values of each selected plasma miRNA as well as of two human endogenous control miR423-5p and miR16-5p, and of exogenous control cel-miR39-3p were measured. The Cq values of the two endogenous controls were compared in order to identify the most stable one to be used to calculate the relative plasma expression: ^Cq = CqmiRNA of interest- Cqendogenous control18. Three step Bayesian approach implementing machine learning (ML) algorithms

[0206] A parallel ML approach was used to validate the results of the leave-one-out cross validation. This second approach included correlation-based feature selection, logistic linear regression with 10-fold Cross Validation, and tree-based model selection of the model with the lowest Akaike Information Criterion (AIC) value. The narrowing of selected circulating compounds (e.g., metabolite and / or proteins) was implemented using Correlational Feature Selection (CFS) (Weka) complemented with the best first attribute selection strategy to evaluate the worth of specific attributes by considering the individual predictive ability of each feature along with the degree of redundancy between them. The CFS method iteratively added attributes with the highest correlation with the class as long as there was not an attribute already in the subset that had a higher correlation with the attribute assessed. The number of consecutive non-improving nodes to allow before terminating the search was set at 5. Attribute selection was performed in 10-fold cross validation mode.

[0207] The multinomial logistic regression model with a ridge estimator (Weka) was applied as the classifier. This was given a binary classification on ^^ samples with ^^ features. The probability for the positive class for any sample ^^ was estimated using:138923491.1 - 69 -where ^^^is the feature vector for sample ^^ and β is the vector of the ^^ coefficients. negative multinomial log-likelihood to be minimized is:where ^^^is the label for sample ^^ and ridge=1.0x10-8.

[0208] A Quasi-Newton Method was used to search for the optimized values of the ^^ features. Missing values were replaced using mean values.

[0209] Given the importance of clinical applicability, a smaller number of compounds with high sensitivity was preferred. Therefore, the AIC was calculated to evaluate each possible model using (1) the mean absolute error estimated from logistic regression classification with 10-fold cross validation, (2) the number of compounds included accounted for the complexity of the model. * * *

[0210] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.138923491.1 - 70 -REFERENCES

[0211] The following references and the references cited throughout the specification, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. 1. Flemming KD, Graff-Radford J, Aakre J, et al. Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults: Mayo Clinic Study of Aging. JAMA Neurol. Jul 12017;74(7):801-805. 2. Akers A, Al-Shahi Salman R, I AA, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery. May 12017;80(5):665-680. 3. Polster SP, Cao Y, Carroll T, et al. Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery. Apr 12019;84(4):954-964. 4. Polster SP, Stadnik A, Akers AL, et al. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. Dec 12019;85(6):843-853. 5. Snellings DA, Hong CC, Ren AA, et al. Cerebral Cavernous Malformation: From Mechanism to Therapy. Circ Res. Jun 252021;129(1):195-215. 6. Al-Shahi Salman R, Hall JM, Horne MA, et al. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol. Mar 2012;11(3):217-24. 7. Horne MA, Flemming KD, Su IC, et al. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol. Feb 2016;15(2):166- 173. 8. Girard R, Li Y, Stadnik A, et al. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. Feb 162021;88(3):686-697. 9. Awad IA, Polster SP. Cavernous angiomas: deconstructing a neurosurgical disease. J Neurosurg. Jul 12019;131(1):1-13.138923491.1 - 71 -10. Koskimaki J, Polster SP, Li Y, et al. Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. Geroscience. Oct 2020;42(5):1351-1363. 11. Tang AT, Choi JP, Kotzin JJ, et al. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. May 182017;545(7654):305-310. 12. Polster SP, Sharma A, Tanes C, et al. Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nat Commun. May 27 2020;11(1):2659. 13. Choquet H, Pawlikowska L, Nelson J, et al. Polymorphisms in inflammatory and immune response genes associated with cerebral cavernous malformation type 1 severity. Cerebrovasc Dis.2014;38(6):433-40. 14. Lopez-Ramirez MA, Pham A, Girard R, et al. Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood. Jan 172019;133(3):193-204. 15. Hong T, Xiao X, Ren J, et al. Somatic MAP3K3 and PIK3CA mutations in sporadic cerebral and spinal cord cavernous malformations. Brain. Oct 222021;144(9):2648-2658. 16. Ren AA, Snellings DA, Su YS, et al. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. Jun 2021;594(7862):271-276. 17. Weng J, Yang Y, Song D, et al. Somatic MAP3K3 mutation defines a subclass of cerebral cavernous malformation. Am J Hum Genet. May 62021;108(5):942-950. 18. Girard R, Zeineddine HA, Fam MD, et al. Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. Feb 2018;9(1):34-43. 19. Girard R, Zeineddine HA, Koskimaki J, et al. Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. Jun 82018;122(12):1716-1721. 20. Lyne SB, Girard R, Koskimaki J, et al. Biomarkers of cavernous angioma with symptomatic hemorrhage. JCI Insight. Jun 202019;4(12):e128577(12) 21. Duarte JM, Schuck PF, Wenk GL, Ferreira GC. Metabolic disturbances in diseases with neurological involvement. Aging Dis. Aug 2014;5(4):238-55. 22. Srivastava S. Emerging Insights into the Metabolic Alterations in Aging Using Metabolomics. Metabolites. Dec 132019;9(12) 23. Kaushik AK, DeBerardinis RJ. Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer. Aug 2018;1870(1):2-14.138923491.1 - 72 -24. Sun YV, Hu YJ. Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases. Adv Genet.2016;93:147-90. 25. Koskimaki J, Girard R, Li Y, et al. Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes. JCI Insight. Feb 7 2019;4(3):e126167(3) 26. Cullere X, Plovie E, Bennett PM, MacRae CA, Mayadas TN. The cerebral cavernous malformation proteins CCM2L and CCM2 prevent the activation of the MAP kinase MEKK3. Proc Natl Acad Sci U S A. Nov 172015;112(46):14284-9. 27. Goitre L, DiStefano PV, Moglia A, et al. Up-regulation of NADPH oxidase-mediated redox signaling contributes to the loss of barrier function in KRIT1 deficient endothelium. Sci Rep. Aug 152017;7(1):8296. 28. Wetzel-Strong SE, Weinsheimer S, Nelson J, et al. Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations. Orphanet J Rare Dis. Sep 32021;16(1):372. 29. Lopez-Ramirez MA, Lai CC, Soliman SI, et al. Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation. J Clin Invest. Jul 1 2021;131(13) 30. Schersten T. The synthesis of taurocholic and glycocholic acids in human liver homogenates and subcellular fractions in obstructive jaundice. Scand J Gastroenterol. 1967;2(1):49-58. 31. Li C, Wang X, Yan J, et al. Cholic Acid Protects In Vitro Neurovascular Units against Oxygen and Glucose Deprivation-Induced Injury through the BDNF-TrkB Signaling Pathway. Oxid Med Cell Longev.2020;2020:1201624. 32. Warden C, Brantley MA, Jr. Glycine-Conjugated Bile Acids Protect RPE Tight Junctions against Oxidative Stress and Inhibit Choroidal Endothelial Cell Angiogenesis In Vitro. Biomolecules. Apr 232021;11(5) 33. Hong CC, Tang AT, Detter MR, et al. Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. J Exp Med. Oct 52020;217(10) 34. Shi C, Shenkar R, Du H, et al. Immune response in human cerebral cavernous malformations. Stroke. May 2009;40(5):1659-65. 35. Wang B, Wu L, Chen J, et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther. Feb 262021;6(1):94.138923491.1 - 73 -36. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation. Mar 27 2007;115(12):1599-608. 37. Tabruyn SP, Griffioen AW. NF-kappa B: a new player in angiostatic therapy. Angiogenesis.2008;11(1):101-6. 38. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics. Sep 2007;3(3):211-221. 39. Schymanski EL, Jeon J, Gulde R, et al. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol. Feb 18 2014;48(4):2097-8. 40. Sehat N, Yurawecz MP, Roach JA, Mossoba MM, Kramer JK, Ku Y. Silver-ion high- performance liquid chromatographic separation and identification of conjugated linoleic acid isomers. Lipids. Feb 1998;33(2):217-21. 41. Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). Feb 2018;243(3):213-221. 42. Girard R, Khanna O, Shenkar R, et al. Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016;10(3):255-64. 43. Al-Shahi Salman R, Berg MJ, Morrison L, Awad IA, Angioma Alliance Scientific Advisory B. Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board. Stroke. Dec 2008;39(12):3222-30. 44. Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. Jul 232010;11:395. 45. Wang M, Carver JJ, Phelan VV, et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat Biotechnol. Aug 92016;34(8):828-837. 46. Nothias LF, Petras D, Schmid R, et al. Feature-based molecular networking in the GNPS analysis environment. Nat Methods. Sep 2020;17(9):905-908. 47. Barker M, Rayens W. Partial least squares for discrimination. J Chemometr. Mar 2003;17(3):166-173. 48. Sulakhe D, Balasubramanian S, Xie B, et al. Lynx: a database and knowledge extraction engine for integrative medicine. Nucleic Acids Res. Jan 2014;42(Database issue):D1007-12.138923491.1 - 74 -49. Shaffer M, Thurimella K, Quinn K, et al. AMON: annotation of metabolite origins via networks to integrate microbiome and metabolome data. BMC Bioinformatics. Nov 28 2019;20(1):614. 50. Rencher AC. Methods of multivariate analysis. John Wiley & Sons, Inc; 2003. 51. Huberty CJ. Applied discriminant analysis. John Wiley & Sons, Inc; 1994. 52. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology. Jan 2005;16(1):73-81. 53. Song E, Won S, Lee W. Using the corrected Akaike's information criterion for model selection. Korean Journal of Applied Statistics. Feb 2017;30(1):119-133.138923491.1 - 75 -

Claims

WHAT IS CLAIMED:

1. A method for treating cavernous angioma (CA) in a subject, the method comprising administering a therapy to a subject that has been evaluated for one or more metabolites and / or one or more biomarkers in a biological sample from the subject; wherein the metabolite comprises one or more of: 1-(9Z-Octadecenoyl)-sn-glycero-3- phosphocholine, Linoleic Acid, 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, Cholic acid, cis-9-Hexadecenoic acid, Etiocholanedione, Glycocholic acid, Glycodeoxycholic acid, Deoxycholic acid, Hydroxypalmitic acid, Hypoxanthine, LysoPE 18:2, Phenylalanylphenylalanine, Tauroursodeoxycholic acid, Urobilin, 1-Oleoyl-sn-glycero-3- phosphoethanolamine, Arachidonic acid (cis-5,8,11,14-Eicosatetraenoic acid), 1-Palmitoyl-sn- glycero-3-phosphocholine, 1-Stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, 7a- Hydroxy-3-oxo-4-cholestenoic acid (7alpha-Hydroxy-3-oxo-4-cholestenoic acid), Bilirubin, cis-9-Hexadecenoic acid, Decanoyl-L-carnitine, palmitoleic acid, LysoPC 18:1, LysoPE 16:0, DL-beta-Hydroxypalmitic acid, LysoPE 18:1, LysoPC 16:0, and LysoPE 18:0; and wherein the biomarker comprises one or more of C-reactive protein (CRP), Endoglin, Interferon gamma (IFNγ), IL-1β, IL-6, IL-7, IL-10, IL-16, IL17, Soluble cluster of differentiation 14 (sCD14), Tumor necrosis factors (TNF), Vascular endothelial growth factor (VEGF), Soluble toll-like receptor4 (sTLR4), Lipopolysaccharide binding protein (LBP), Thrombomodulin, Thrombospondin-1 (TSP-1), Thrombospondin-2 (TSP-2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), miR-25-3p, miR-4732-3p, miR-486-3p, miR-486-5p, miR- 7706, miR-144-5p, miR-92a-3p, miR-16-5p, miR-182-5p, miR-1180-3p, miR-629-5p, miR- 151b, miR-183-5p, miR-20a-5p, miR-30d-5p, miR-451a, miR-660-5p, miR-501-3p, and miR- 144-3p.

2. The method of claim 1, wherein the subject has been evaluated for levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486-5p.

3. The method of claim 1 or 2, wherein the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486-5p relative to a control.

4. The method of claim 2 or 3, wherein the subject has been determined to have a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10]+316.54*[Linoleic Acid]r,-6.06*[miR-20a-5p]r+5.41*[mir-25- 3p]r+1.26*[miR-486-5p]r.138923491.1 - 76 -5. The method of any one of claims 1-4, wherein the subject has been evaluated for levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a- 3p, miR-25-3p, and miR-486-5p.

6. The method of any one of claims 1-5, wherein the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, and miR-486-5p relative to a control.

7. The method of claim 5 or 6, wherein the subject has been determined to have a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10]+336051.67*[Linoleic Acid]r,-19317.97*[glycodeoxycholic acid]r-6074*[miR-92a-3p]r+74219*[miR-25-3p]r+3248.33*[miR-486-5p]r.

8. The method of any one of claims 1-7, wherein the subject has been evaluated for levels of one or more of sCD14, CRP, VEGF, and IL-10.

9. The method of any one of claims 1-8, wherein the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, and IL-10 relative to a control.

10. The method of claim 8 or 9, wherein the subject has been determined to have a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10].

11. The method of any one of claims 1-10, wherein the subject has been evaluated for levels of one or more of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and miR-486-5p.

12. The method of any one of claims 1-11, wherein the subject has been evaluated as having differential levels of one or more of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and miR-486-5p relative to a control.

13. The method of claim 11 or 12, wherein the subject has been determined to have a canonical value, wherein the canonical value is equal to 0.55*[ miR-16-5p]r-1.44*[miR-20a- 5p]r+1.38*[miR-25-3p]r-1.04*[miR-92a-3p]r+0.57*[miR-486-5p]r.

14. The method of any one of claims 1-13, wherein the subject has been evaluated for levels of one or more of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid.

15. The method of any one of claims 1-14, wherein the subject has been evaluated as having differential levels of one or more of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid relative to a control.

16. The method of claim 14 or 15, wherein the subject has been determined to have a canonical value, wherein the canonical value is equal to -1248.41*[oleoyl-sn-glycero-3- phosphoethanolamine]r-17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r.138923491.1 - 77 -17. The method of any one of claims 1-16, wherein the subject has been evaluated for levels of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a- hydroxy-3-oxo-4-cholestenoic acid.

18. The method of any one of claims 1-17, wherein the subject has been evaluated as having differential levels of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy-3-oxo-4-cholestenoic acid relative to a control.

19. The method of claim 17 or 18, wherein the subject has been determined to have a canonical value, wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a- hydroxy-3-oxo-4-cholestenoic acid] + 0.

07.

20. The method of any one of claims 1-19, wherein the subject has been evaluated for levels of one or more of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, and bilirubin.

21. The method of any one of claims 1-20, wherein the subject has been evaluated as having differential levels of one or more of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3- phosphocholine, and bilirubin relative to a control.

22. The method of claim 20 or 21, wherein the subject has been determined to have a canonical value, wherein the canonical value is equal to 3682.02 * [cis-9-hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn-glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.

48.

23. The method of any one of claims 1-22, wherein the subject has been evaluated for levels of decanoyl-L-carnitine.

24. The method of any one of claims 1-23, wherein the subject has been evaluated as having differential levels of decanoyl-L-carnitine relative to a control.

25. The method of claim 23 or 24, wherein the subject has been determined to have a canonical value, wherein the canonical value is equal to 1236.91 * [decanoyl-L-carnitine] – 0.

37.

26. The method of any one of claims 4-25, wherein the canonical value is determined to be greater than -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

27. The method of any one of claims 4-25, wherein the canonical value is determined to be less than -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

28. The method of any one of claims 1-27, wherein the biomarker or metabolite is determined to have differential levels relative to a control.138923491.1 - 78 -29. The method of any one of claims 1-27, wherein the biomarker or metabolite is determined to have levels not significantly different than a control.

30. The method of any one of claims 1-28, wherein the biomarker or metabolite is increased relative to a control.

31. The method of any one of claims 1-28, wherein the biomarker or metabolite is decreased relative to a control.

32. The method of any one of claims 1-31, wherein the subject has been diagnosed with CA.

33. The method of any one of claims 1-31, wherein the subject has not been diagnosed with CA.

34. The method of any one of claims 1-33, wherein the CA is further defined as CA with symptomatic hemorrhage (CASH).

35. The method of any one of claims 1-34, wherein the CA is further defined as CA without symptomatic hemorrhage (non-CASH) 36. The method of any one of claims 1-35, wherein the CA is further defined as non- aggressive CA.

37. The method of any one of claims 1-35, wherein the CA is further defined as aggressive CA.

38. The method of any one of claims 1-37, wherein CA is further defined as familial CA or sporadic CA.

39. The method of claim 38, wherein the familial CA is further define as familial-CCM1.

40. The method of claim 38, wherein the familial CA is further define as familial-CCM3.

41. The method of any one of claims 1-40, wherein the subject is being treated with a therapy for CA.

42. The method of any one of claims 1-40, wherein the subject is not being treated with a therapy for CA.

43. The method of any one of claims 1-42, wherein the sample from the subject comprises a tissue sample, a blood sample, a whole blood sample, a fractionated sample, a plasma sample, a fecal sample, or a urine sample.

44. The method of any one of claims 1-43, wherein the sample from the subject comprises a plasma sample from the subject.

45. The method of any of claims 1-44, wherein the expression level of no other biomarker in the sample was determined.138923491.1 - 79 -46. The method of any one of claims 3-45, wherein the control comprises the level of the metabolite or biomarker in samples from subjects identified as non-CASH, low risk, as not having CA, or as having non-aggressive CA.

47. The method of any one of claims 3-46, wherein the control comprises the expression or protein level of the biomarker in samples from subjects identified as CASH, high risk, as having CA, or as having aggressive CA.

48. The method of any one of claims 1-47, wherein the treatment comprises a gene therapy, a B-cell immunomodulation therapy, surgical excision of a CCM lesion, or combinations thereof.

49. A method for prognosing or diagnosing CA, aggressive CA, non-aggressive CA, CASH or non-CASH, familial CA, or sporadic CA in a subject, the method comprising evaluating one or more metabolites and / or one or more biomarkers in a biological sample from the subject; wherein the metabolite comprises one or more of 1-(9Z-Octadecenoyl)-sn-glycero-3- phosphocholine, Linoleic Acid, 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, Cholic acid, cis-9-Hexadecenoic acid, Etiocholanedione, Glycocholic acid, Glycodeoxycholic acid, Deoxycholic acid, Hydroxypalmitic acid, Hypoxanthine, LysoPE 18:2, Phenylalanylphenylalanine, Tauroursodeoxycholic acid, Urobilin, 1-Oleoyl-sn-glycero-3- phosphoethanolamine, Arachidonic acid (cis-5,8,11,14-Eicosatetraenoic acid), 1-Palmitoyl-sn- glycero-3-phosphocholine, 1-Stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, 7a- Hydroxy-3-oxo-4-cholestenoic acid (7alpha-Hydroxy-3-oxo-4-cholestenoic acid), Bilirubin, cis-9-Hexadecenoic acid, Decanoyl-L-carnitine, palmitoleic acid, LysoPC 18:1, LysoPE 16:0, DL-beta-Hydroxypalmitic acid, LysoPE 18:1, LysoPC 16:0, and LysoPE 18:0; and wherein the biomarker comprises one or more of C-reactive protein (CRP), Endoglin, Interferon gamma (IFNγ), IL-1β, IL-6, IL-7, IL-10, IL-16, IL17, Soluble cluster of differentiation 14 (sCD14), Tumor necrosis factors (TNF), Vascular endothelial growth factor (VEGF), Soluble toll-like receptor4 (sTLR4), Lipopolysaccharide binding protein (LBP), Thrombomodulin, Thrombospondin-1 (TSP-1), Thrombospondin-2 (TSP-2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), miR-25-3p, miR-4732-3p, miR-486-3p, miR-486-5p, miR- 7706, miR-144-5p, miR-92a-3p, miR-16-5p, miR-182-5p, miR-1180-3p, miR-629-5p, miR- 151b, miR-183-5p, miR-20a-5p, miR-30d-5p, miR-451a, miR-660-5p, miR-501-3p, and miR- 144-3p.

50. The method of claim 49, wherein the subject has been evaluated for levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486-5p.138923491.1 - 80 -51. The method of claim 49 or 50, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486-5p relative to a control.

52. The method of claim 50 or 51, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, wherein the canonical value is equal to - 3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10]+316.54*[Linoleic Acid]r,- 6.06*[miR-20a-5p]r+5.41*[mir-25-3p]r+1.26*[miR-486-5p]r.

53. The method of any one of claims 49-52, wherein the subject has been evaluated for levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, and miR-486-5p.

54. The method of claim 53, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR- 25-3p, and miR-486-5p relative to a control.

55. The method of claim 53 or 54, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -4, -3, -2, -1, 0, 1, 2, or 3, wherein the canonical value is equal to - 3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10]+336051.67*[Linoleic Acid]r,- 19317.97*[glycodeoxycholic acid]r-6074*[miR-92a-3p]r+74219*[miR-25- 3p]r+3248.33*[miR-486-5p]r.

56. The method of any one of claims 49-55, wherein the subject has been evaluated for levels of one or more of sCD14, CRP, VEGF, and IL-10.

57. The method of claim 56, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of sCD14, CRP, VEGF, and IL-10 relative to a control.

58. The method of claim 56 or 57, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -8, -7, -6, -5, -4, -3, or -2, wherein the canonical value is equal to - 3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10].

59. The method of any one of claims 49-58, wherein the subject has been evaluated for levels of one or more of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and miR-486-5p.138923491.1 - 81 -60. The method of claim 59, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and miR-486-5p relative to a control.

61. The method of claim 59 or 60, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -2, -1, 0, 1, 2, or 3 wherein the canonical value is equal to 0.55*[ miR-16-5p]r-1.44*[miR- 20a-5p]r+1.38*[miR-25-3p]r-1.04*[miR-92a-3p]r+0.57*[miR-486-5p]r.

62. The method of any one of claims 49-61, wherein the subject has been evaluated for levels of one or more of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid.

63. The method of claim 62, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid relative to a control.

64. The method of claim 62 or 63, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -2, -1.75, -1.5, -1.25, -1, -0.75, -0.5, -0.25, or 0, wherein the canonical value is equal to - 1248.41*[oleoyl-sn-glycero-3-phosphoethanolamine]r-17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r.

65. The method of any one of claims 49-64, wherein the CA is further defined as CASH.

66. The method of claim 50, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486- 5p relative to a control.

67. The method of claim 50 or 66, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10]+316.54*[Linoleic Acid]r,- 6.06*[miR-20a-5p]r+5.41*[mir-25-3p]r+1.26*[miR-486-5p]r.

68. The method of claim 53, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, and miR-486-5p relative to a control.138923491.1 - 82 -69. The method of claim 53 or 68, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than 3, 2, 1, 0, -1, -2, -3, or -4, wherein the canonical value is equal to - 3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10]+336051.67*[Linoleic Acid]r,- 19317.97*[glycodeoxycholic acid]r-6074*[miR-92a-3p]r+74219*[miR-25- 3p]r+3248.33*[miR-486-5p]r.

70. The method of claim 56, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of sCD14, CRP, VEGF, and IL-10 relative to a control.

71. The method of claim 56 or 70, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than -3, -4, -5, -6, -7, or -8, wherein the canonical value is equal to - 3.37*[sCD14]+1.47*[CRP]-0.36*[VEGF]-0.57*[IL-10].

72. The method of claim 59, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and miR-486-5p relative to a control.

73. The method of claim 59 or 72, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than 0, -0.25, -0.5, -0.75, -1, -1.25, -1.5, -1.75, -2, -2.25, -2.5, -2.75, or 3, wherein the canonical value is equal to 0.55*[ miR-16-5p]r-1.44*[miR-20a-5p]r+1.38*[miR-25-3p]r- 1.04*[miR-92a-3p]r+0.57*[miR-486-5p]r.

74. The method of claim 62, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as not having differential levels of one or more of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid relative to a control.

75. The method of claim 62 or 74, wherein the subject is diagnosed as having non-CASH when a biological sample from the subject has been evaluated as having a canonical value of less than 0, -0.25, -0.5, -0.75, -1, -1.25, -1.5, -1.75, -2, -2.25, -2.5, -2.75, or 3, wherein the canonical value is equal to -1248.41*[oleoyl-sn-glycero-3-phosphoethanolamine]r- 17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r.

76. The method of any one of claims 49-75, wherein the subject has been evaluated for levels of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a- hydroxy-3-oxo-4-cholestenoic acid.138923491.1 - 83 -77. The method of any one of claims 49-76, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having differential levels of one or more of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy- 3-oxo-4-cholestenoic acid relative to a control.

78. The method of claim 76 or 77, wherein the subject is diagnosed as having CA when a biological sample from the subject has been evaluated as having a canonical value of greater than greater than -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4-cholestenoic acid] + 0.

07.

79. The method of claim 76, wherein the subject is diagnosed as not having CA when a biological sample from the subject has been evaluated as not having differential levels of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy-3-oxo-4- cholestenoic acid relative to a control.

80. The method of claim 62 or 74, wherein the subject is diagnosed as not having CA when a biological sample from the subject has been evaluated as having a canonical value of less than less than -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a-hydroxy-3-oxo-4-cholestenoic acid] + 0.

07.

81. The method of any one of claims 49-80, wherein the subject has been evaluated for levels of one or more of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, and bilirubin.

82. The method of claim 81, wherein the subject is diagnosed as having aggressive CA when a biological sample from the subject has been evaluated as having differential levels of one or more of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, and bilirubin relative to a control.

83. The method of claim 81 or 82, wherein the subject is diagnosed as having aggressive CA when a biological sample from the subject has been evaluated as having a canonical value of less than -5, -4.5, -4, -3.5, -3, -2.5, -2, -1.5, -1, -0.5, 0, 0.5, 1, 1.5, 2, 2.5, or 3, wherein the138923491.1 - 84 -canonical value is equal to 3682.02 * [cis-9-hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn- glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.

48.

84. The method of claim 81, wherein the subject is diagnosed as having non-aggressive CA when a biological sample from the subject has been evaluated as not having differential levels of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, and bilirubin relative to a control.

85. The method of claim 81 or 84, wherein the subject is diagnosed as having non- aggressive CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -5, -4.5, -4, -3.5, -3, -2.5, -2, -1.5, -1, -0.5, 0, 0.5, 1, 1.5, 2, 2.5, or 3, wherein the canonical value is equal to 3682.02 * [cis-9-hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn-glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.

48.

86. The method of any one of claims 49-85, wherein the subject has been evaluated for levels of decanoyl-L-carnitine.

87. The method of claim 81, wherein the subject is diagnosed as having familial CA when a biological sample from the subject has been evaluated as having differential levels of decanoyl-L-carnitine relative to a control.

88. The method of claim 81 or 82, wherein the subject is diagnosed as having familial CA when a biological sample from the subject has been evaluated as having a canonical value of greater than -2, -1.5, -1, -0.5, 0, 0.5, or 1, wherein the canonical value is equal to 1236.91 * [decanoyl-L-carnitine] – 0.

37.

89. The method of claim 86, wherein the subject is diagnosed as having sporadic CA when a biological sample from the subject has been evaluated as not having differential levels of decanoyl-L-carnitine relative to a control.

90. The method of claim 86 or 87, wherein the subject is diagnosed as having sporadic CA when a biological sample from the subject has been evaluated as having a canonical value of less than -2, -1.5, -1, -0.5, 0, 0.5, or 1, wherein the canonical value is equal to 1236.91 * [decanoyl-L-carnitine] – 0.

37.

91. The method of any one of claims 49-90, wherein the biomarker or metabolite is determined to have differential levels relative to a control.

92. The method of any one of claims 49-90, wherein the biomarker or metabolite is determined to have levels not significantly different than a control.

93. The method of any one of claims 49-92, wherein the biomarker or metabolite is increased relative to a control.138923491.1 - 85 -94. The method of any one of claims 49-92, wherein the biomarker or metabolite is decreased relative to a control.

95. The method of any one of claims 49-94, wherein the subject has been diagnosed with CA.

96. The method of any one of claims 49-94, wherein the subject has not been diagnosed with CA.

97. The method of any one of claims 87-96, wherein the familial CA is further define as familial-CCM1.

98. The method of any one of claims 87-96, wherein the familial CA is further define as familial-CCM3.

99. The method of any one of claims 49-98, wherein the subject is being treated with a therapy for CA or wherein the method further comprises treating a subject with a CA therapy.

100. The method of any one of claims 49-98, wherein the subject is not being treated with a therapy for CA.

101. The method of any one of claims 49-100, wherein the sample from the subject comprises a tissue sample, a blood sample, a whole blood sample, a fractionated sample, a plasma sample, a fecal sample, or a urine sample.

102. The method of any one of claims 49-101, wherein the sample from the subject comprises a plasma sample from the subject.

103. The method of any of claims 49-102, wherein the expression level of no other biomarker or metabolite in the sample was determined.

104. The method of any one of claims 51-103, wherein the control comprises the level of the metabolite or biomarker in samples from subjects identified as having non-CASH, in subject identified as low risk, in subjects identified as not having CA, subject identified as having non- aggressive CA, or in subjects having familial CA.

105. The method of any one of claims 51-103, wherein the control comprises the expression or protein level of the biomarker in samples from subjects identified as high risk, in subject identified as having CASH, in subjects identified as having CA, in subject identified as having aggressive CA, or in subjects identified as having sporadic CA.

106. The method of any one of claims 99-105, wherein the therapy comprises a gene therapy, a B-cell immunomodulation therapy, surgical excision of a CCM lesion, or combinations thereof.

107. A method for evaluating a subject comprising evaluating one or more metabolites and / or one or more biomarkers in a biological sample from the subject;138923491.1 - 86 -wherein the metabolite comprises one or more of: 1-(9Z-Octadecenoyl)-sn-glycero-3- phosphocholine, Linoleic Acid, 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, Cholic acid, cis-9-Hexadecenoic acid, Etiocholanedione, Glycocholic acid, Glycodeoxycholic acid, Deoxycholic acid, Hydroxypalmitic acid, Hypoxanthine, LysoPE 18:2, Phenylalanylphenylalanine, Tauroursodeoxycholic acid, Urobilin, 1-Oleoyl-sn-glycero-3- phosphoethanolamine, Arachidonic acid (cis-5,8,11,14-Eicosatetraenoic acid), 1-Palmitoyl-sn- glycero-3-phosphocholine, 1-Stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, 7a- Hydroxy-3-oxo-4-cholestenoic acid (7alpha-Hydroxy-3-oxo-4-cholestenoic acid), Bilirubin, cis-9-Hexadecenoic acid, Decanoyl-L-carnitine, palmitoleic acid, LysoPC 18:1, LysoPE 16:0, DL-beta-Hydroxypalmitic acid, LysoPE 18:1, LysoPC 16:0, and LysoPE 18:0; and wherein the biomarker comprises one or more of C-reactive protein (CRP), Endoglin, Interferon gamma (IFNγ), IL-1β, IL-6, IL-7, IL-10, IL-16, IL17, Soluble cluster of differentiation 14 (sCD14), Tumor necrosis factors (TNF), Vascular endothelial growth factor (VEGF), Soluble toll-like receptor4 (sTLR4), Lipopolysaccharide binding protein (LBP), Thrombomodulin, Thrombospondin-1 (TSP-1), Thrombospondin-2 (TSP-2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), miR-25-3p, miR-4732-3p, miR-486-3p, miR-486-5p, miR- 7706, miR-144-5p, miR-92a-3p, miR-16-5p, miR-182-5p, miR-1180-3p, miR-629-5p, miR- 151b, miR-183-5p, miR-20a-5p, miR-30d-5p, miR-451a, miR-660-5p, miR-501-3p, and miR- 144-3p.

108. A method for monitoring a response to CA therapy in a subject having CA, the method comprising evaluating one or more metabolites and / or one or more biomarkers in a biological sample from the subject before and / or after the subject has been treated with the CA therapy; wherein the metabolite comprises one or more of: 1-(9Z-Octadecenoyl)-sn-glycero-3- phosphocholine, Linoleic Acid, 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, Cholic acid, cis-9-Hexadecenoic acid, Etiocholanedione, Glycocholic acid, Glycodeoxycholic acid, Deoxycholic acid, Hydroxypalmitic acid, Hypoxanthine, LysoPE 18:2, Phenylalanylphenylalanine, Tauroursodeoxycholic acid, Urobilin, 1-Oleoyl-sn-glycero-3- phosphoethanolamine, Arachidonic acid (cis-5,8,11,14-Eicosatetraenoic acid), 1-Palmitoyl-sn- glycero-3-phosphocholine, 1-Stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, 7a- Hydroxy-3-oxo-4-cholestenoic acid (7alpha-Hydroxy-3-oxo-4-cholestenoic acid), Bilirubin, cis-9-Hexadecenoic acid, Decanoyl-L-carnitine, palmitoleic acid, LysoPC 18:1, LysoPE 16:0, DL-beta-Hydroxypalmitic acid, LysoPE 18:1, LysoPC 16:0, and LysoPE 18:0; and wherein the biomarker comprises one or more of C-reactive protein (CRP), Endoglin, Interferon gamma (IFNγ), IL-1β, IL-6, IL-7, IL-10, IL-16, IL17, Soluble cluster of138923491.1 - 87 -differentiation 14 (sCD14), Tumor necrosis factors (TNF), Vascular endothelial growth factor (VEGF), Soluble toll-like receptor4 (sTLR4), Lipopolysaccharide binding protein (LBP), Thrombomodulin, Thrombospondin-1 (TSP-1), Thrombospondin-2 (TSP-2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), miR-25-3p, miR-4732-3p, miR-486-3p, miR-486-5p, miR- 7706, miR-144-5p, miR-92a-3p, miR-16-5p, miR-182-5p, miR-1180-3p, miR-629-5p, miR- 151b, miR-183-5p, miR-20a-5p, miR-30d-5p, miR-451a, miR-660-5p, miR-501-3p, and miR- 144-3p.

109. The method of claim 107 or 108, wherein the evaluated biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and miR-486-5p.

110. The method of any one of claims 107-109, wherein the evaluated biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, miR-486-5p, and / or one or more control(s).

111. The method of claim 109 or 110, wherein the method further comprises determining a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10]+316.54*[Linoleic Acid]r,-6.06*[miR-20a-5p]r+5.41*[mir-25- 3p]r+1.26*[miR-486-5p]r.

112. The method of any one of claims 107-111, wherein the evaluated biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, and miR-486-5p.

113. The method of any one of claims 107-112, wherein the evaluated biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, miR-486-5p, and / or one or more control(s).

114. The method of claim 112 or 113, wherein the method further comprises determining a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10]+336051.67*[Linoleic Acid]r,-19317.97*[glycodeoxycholic acid]r-6074*[miR-92a-3p]r+74219*[miR-25-3p]r+3248.33*[miR-486-5p]r.

115. The method of any one of claims 107-114, wherein the evaluated biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, and IL-10.

116. The method of any one of claims 107-112, wherein the evaluated biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, and / or one or more control(s).

117. The method of claim 115 or 116, wherein the method further comprises determining a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10].138923491.1 - 88 -118. The method of any one of claims 107-117, wherein the evaluated biomarkers or metabolites comprise or consist of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and miR- 486-5p.

119. The method of any one of claims 107-118, wherein the evaluated biomarkers or metabolites comprise or consist of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, miR- 486-5p, and / or one or more control(s).

120. The method of claim 118 or 119, wherein the method further comprises determining a canonical value, wherein the canonical value is equal to 0.55*[ miR-16-5p]r-1.44*[miR-20a- 5p]r+1.38*[miR-25-3p]r-1.04*[miR-92a-3p]r+0.57*[miR-486-5p]r.

121. The method of any one of claims 107-120, wherein the evaluated biomarkers or metabolites comprise or consist of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, and linoleic acid.

122. The method of any one of claims 107-121, wherein the evaluated biomarkers or metabolites comprise or consist of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, linoleic acid, and / or one or more control(s).

123. The method of claim 121 or 122, wherein the method further comprises determining a canonical value, wherein the canonical value is equal to -1248.41*[oleoyl-sn-glycero-3- phosphoethanolamine]r-17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r.

124. The method of any one of claims 107-123, wherein the evaluated biomarkers or metabolites comprise or consist of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and 7a-hydroxy-3-oxo-4-cholestenoic acid.

125. The method of any one of claims 107-124, wherein the evaluated biomarkers or metabolites comprise or consist of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, 7a-hydroxy-3-oxo-4-cholestenoic acid, and / or one or more control(s).

126. The method of claim 124 or 125, wherein the method further comprises determining a canonical value, wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a- hydroxy-3-oxo-4-cholestenoic acid] + 0.

07.

127. The method of any one of claims 107-126, wherein the evaluated biomarkers or metabolites comprise or consist of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3- phosphocholine, and bilirubin.

128. The method of any one of claims 107-127, wherein the evaluated biomarkers or metabolites comprise or consist of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3- phosphocholine, bilirubin, and / or one or more control(s).138923491.1 - 89 -129. The method of claim 127 or 128, wherein the method further comprises determining a canonical value, wherein the canonical value is equal to 3682.02 * [cis-9-hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn-glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.

48.

130. The method of any one of claims 107-129, wherein the evaluated biomarkers or metabolites comprise or consist of decanoyl-L-carnitine.

131. The method of any one of claims 107-130, wherein the evaluated biomarkers or metabolites comprise or consist of decanoyl-L-carnitine and one or more control(s).

132. The method of claim 130 or 131, wherein the method further comprises determining a canonical value, wherein the canonical value is equal to 1236.91 * [decanoyl-L-carnitine] – 0.

37.

133. The method of any one of claims 107-132, wherein the biomarker or metabolite is evaluated as having differential levels relative to a control.

134. The method of any one of claims 107-132, wherein the biomarker or metabolite is evaluated as having levels not significantly different than a control.

135. The method of any one of claims 107-132, wherein the biomarker or metabolite is evaluated as being increased relative to a control.

136. The method of any one of claims 107-132, wherein the biomarker or metabolite is evaluated as being decreased relative to a control.

137. The method of any one of claims 107-136, wherein the subject has been diagnosed with CA.

138. The method of any one of claims 107-136, wherein the subject has not been diagnosed with CA.

139. The method of any one of claims 107-138, wherein the CA is further defined as CA with symptomatic hemorrhage (CASH).

140. The method of any one of claims 107-138, wherein the CA is further defined as CA without symptomatic hemorrhage (non-CASH) 141. The method of any one of claims 107-140, wherein the CA is further defined as non- aggressive CA.

142. The method of any one of claims 107-140, wherein the CA is further defined as aggressive CA.

143. The method of any one of claims 107-142, wherein CA is further defined as familial CA or sporadic CA.

144. The method of claim 143, wherein the familial CA is further define as familial-CCM1.

145. The method of claim 143, wherein the familial CA is further define as familial-CCM3.138923491.1 - 90 -146. The method of any one of claims 107-145, wherein the subject is being treated with a therapy for CA.

147. The method of any one of claims 107-145, wherein the subject is not being treated with a therapy for CA.

148. The method of any one of claims 107-147, wherein the sample from the subject comprises a tissue sample, a blood sample, a whole blood sample, a fractionated sample, a plasma sample, a fecal sample, or a urine sample.

149. The method of any one of claims 107-148, wherein the sample from the subject comprises a plasma sample from the subject.

150. The method of any of claims 107-149, wherein the expression level of no other biomarker in the sample was determined.

151. The method of any one of claims 110-150, wherein the control comprises the level of the metabolite or biomarker in samples from subjects identified as non-CASH, subject identified as low risk, in subjects identified as not having CA, or in subject identified as having non-aggressive CA.

152. The method of any one of claims 110-151, wherein the control comprises the expression or protein level of the biomarker in samples from subjects identified as CASH, subject identified as high risk, in subjects identified as having CA, or in subject identified as having aggressive CA.

153. The method of any one of claims 146-152, wherein the therapy comprises a gene therapy, a B-cell immunomodulation therapy, surgical excision of a CCM lesion, or combinations thereof.

154. A kit comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 detection agents for determining levels of one or more biomarkers or metabolites for CCM, wherein the metabolite comprises one or more of: 1-(9Z-Octadecenoyl)-sn-glycero-3- phosphocholine, Linoleic Acid, 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, Cholic acid, cis-9-Hexadecenoic acid, Etiocholanedione, Glycocholic acid, Glycodeoxycholic acid, Deoxycholic acid, Hydroxypalmitic acid, Hypoxanthine, LysoPE 18:2, Phenylalanylphenylalanine, Tauroursodeoxycholic acid, Urobilin, 1-Oleoyl-sn-glycero-3- phosphoethanolamine, Arachidonic acid (cis-5,8,11,14-Eicosatetraenoic acid), 1-Palmitoyl-sn- glycero-3-phosphocholine, 1-Stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, 7a- Hydroxy-3-oxo-4-cholestenoic acid (7alpha-Hydroxy-3-oxo-4-cholestenoic acid), Bilirubin,138923491.1 - 91 -cis-9-Hexadecenoic acid, Decanoyl-L-carnitine, palmitoleic acid, LysoPC 18:1, LysoPE 16:0, DL-beta-Hydroxypalmitic acid, LysoPE 18:1, LysoPC 16:0, and LysoPE 18:0; and wherein the biomarker comprises one or more of C-reactive protein (CRP), Endoglin, Interferon gamma (IFNγ), IL-1β, IL-6, IL-7, IL-10, IL-16, IL17, Soluble cluster of differentiation 14 (sCD14), Tumor necrosis factors (TNF), Vascular endothelial growth factor (VEGF), Soluble toll-like receptor4 (sTLR4), Lipopolysaccharide binding protein (LBP), Thrombomodulin, Thrombospondin-1 (TSP-1), Thrombospondin-2 (TSP-2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), miR-25-3p, miR-4732-3p, miR-486-3p, miR-486-5p, miR- 7706, miR-144-5p, miR-92a-3p, miR-16-5p, miR-182-5p, miR-1180-3p, miR-629-5p, miR- 151b, miR-183-5p, miR-20a-5p, miR-30d-5p, miR-451a, miR-660-5p, miR-501-3p, and miR- 144-3p.

155. The kit of claim 154, wherein the kit further comprises one or more negative or positive control samples and / or control detection agents.

156. The kit of claim 154 or 155, wherein the kit further comprises instructions for use.

157. The kit of any one of claims 154-156, wherein the biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, and / or miR- 486-5p.

158. The kit of any one of claims 154-157, wherein the biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, miR-20a-5p, mir-25-3p, miR-486-5p, and / or one or more control(s).

159. The kit of any one of claims 156-158, wherein the instructions comprises evaluating a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10]+316.54*[Linoleic Acid]r,-6.06*[miR-20a-5p]r+5.41*[mir-25- 3p]r+1.26*[miR-486-5p]r.

160. The kit of any one of claims 154-159, wherein the biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, and / or miR-486-5p.

161. The kit of any one of claims 154-160, wherein the biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, Linoleic Acid, glycodeoxycholic acid, miR-92a-3p, miR-25-3p, miR-486-5p, and / or one or more control(s).

162. The kit of any one of claims 156-161, wherein the instructions comprises evaluating a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10]+336051.67*[Linoleic Acid]r,-19317.97*[glycodeoxycholic acid]r-6074*[miR-92a-3p]r+74219*[miR-25-3p]r+3248.33*[miR-486-5p]r.138923491.1 - 92 -163. The kit of any one of claims 154-162, wherein the biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, and / or IL-10.

164. The kit of any one of claims 154-163, wherein the biomarkers or metabolites comprise or consist of sCD14, CRP, VEGF, IL-10, and / or one or more control(s).

165. The kit of any one of claims 156-164, wherein the instructions comprises evaluating a canonical value, wherein the canonical value is equal to -3.37*[sCD14]+1.47*[CRP]- 0.36*[VEGF]-0.57*[IL-10].

166. The kit of any one of claims 154-165, wherein the biomarkers or metabolites comprise or consist of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, and / or miR-486-5p.

167. The kit of any one of claims 154-166, wherein the biomarkers or metabolites comprise or consist of miR-16-5p, miR-20a-5p, miR-25-3p, miR-92a-3p, miR-486-5p, and / or one or more control(s).

168. The kit of any one of claims 156-167, wherein the instructions comprises evaluating a canonical value, wherein the canonical value is equal to 0.55*[ miR-16-5p]r-1.44*[miR-20a- 5p]r+1.38*[miR-25-3p]r-1.04*[miR-92a-3p]r+0.57*[miR-486-5p]r.

169. The kit of any one of claims 154-168, wherein the biomarkers or metabolites comprise or consist of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, and / or linoleic acid.

170. The kit of any one of claims 154-169, wherein the biomarkers or metabolites comprise or consist of oleoyl-sn-glycero-3-phosphoethanolamine, glycodeoxycholic acid, linoleic acid, and / or one or more control(s).

171. The kit of any one of claims 156-170, wherein the instructions comprises evaluating a canonical value, wherein the canonical value is equal to -1248.41*[oleoyl-sn-glycero-3- phosphoethanolamine]r-17.93*[glycodeoxycholic acid]r+32.63*[linoleic acid]r.

172. The kit of any one of claims 154-171, wherein the biomarkers or metabolites comprise or consist of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, and / or 7a-hydroxy- 3-oxo-4-cholestenoic acid.

173. The kit of any one of claims 154-172, wherein the biomarkers or metabolites comprise or consist of linoleic acid, glycocholic acid, hydroxypalmitic acid, urobilin, 7a-hydroxy-3-oxo- 4-cholestenoic acid, and / or one or more control(s).

174. The kit of any one of claims 156-173, wherein the instructions comprises evaluating a canonical value, wherein the canonical value is equal to 858.65 * [linoleic acid] + 1005.39 * [glycocholic acid] + 1091.07 * [hydroxypalmitic acid] – 1857.99 * [urobilin] – 2145.29 * [7a- hydroxy-3-oxo-4-cholestenoic acid] + 0.07.138923491.1 - 93 -175. The kit of any one of claims 154-174, wherein the biomarkers or metabolites comprise or consist of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, and / or bilirubin.

176. The kit of any one of claims 154-175, wherein the biomarkers or metabolites comprise or consist of cis-9-hexadecenoic acid, 1-palmitoyl-sn-glycero-3-phosphocholine, bilirubin, and / or one or more control(s).

177. The kit of any one of claims 156-176, wherein the instructions comprises evaluating a canonical value, wherein the canonical value is equal to 3682.02 * [cis-9-hexadecenoic acid] – 19165.94 * [1-palmitoyl-sn-glycero-3-phosphocholine] + 962.10 * [bilirubin] – 0.

48.

178. The kit of any one of claims 154-177, wherein the biomarkers or metabolites comprise or consist of decanoyl-L-carnitine.

179. The kit of any one of claims 154-178, wherein the biomarkers or metabolites comprise or consist of decanoyl-L-carnitine and one or more control(s).

180. The kit of any one of claims 156-179, wherein the instructions comprises evaluating a canonical value, wherein the canonical value is equal to 1236.91 * [decanoyl-L-carnitine] – 0.

37.

181. The kit of any one of claims 154-180, wherein the kit comprises reagents for isolation and / or amplification of biomarkers and / or metabolites from a biological sample.

182. The kit of claim 181, wherein the biological sample comprises a tissue sample, a blood sample, a whole blood sample, a fractionated sample, a plasma sample, a fecal sample, or a urine sample.

183. The kit of claim 182, wherein the biological sample comprises a plasma sample.

184. The kit of claim 183, wherein the biological sample is from a subject.

185. The kit of any one of claims 154-184, wherein the kit excludes reagents for detection of any other biomarkers or metabolites.

186. The kit of claim 184 or 185, wherein the subject has been diagnosed with CA.

187. The kit of claim 184 or 185, wherein the subject has not been diagnosed with CA.

188. The kit of any one of claims 154-187, wherein the CA is further defined as CA with symptomatic hemorrhage (CASH).

189. The kit of any one of claims 154-187, wherein the CA is further defined as CA without symptomatic hemorrhage (non-CASH) 190. The kit of any one of claims 154-189, wherein the CA is further defined as non- aggressive CA.138923491.1 - 94 -191. The kit of any one of claims 154-190, wherein the CA is further defined as aggressive CA.

192. The kit of any one of claims 184-191, wherein CA is further defined as familial CA or sporadic CA.

193. The kit of claim 192, wherein the familial CA is further define as familial-CCM1.

194. The kit of claim 192, wherein the familial CA is further define as familial-CCM3.

195. The kit of any one of claims 184-194, wherein the subject is being treated with a therapy for CA.

196. The kit of any one of claims 184-194, wherein the subject is not being treated with a therapy for CA.138923491.1 - 95 -